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Abbreviations used: 
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EXECUTIVE SUMMARY 
Legislation or draft proposals in for instance Europe, Japan and the USA require that 
chemicals are tested for their ability to disrupt the hormonal systems of mammals. Such 
chemicals are hormonally-active and are known as endocrine disruptors (EDs). A widely 
accepted definition of an ED was proposed in 1996 in Weybridge: “An endocrine disruptor 
is an exogenous substance that causes adverse health effects in an intact organism, or its 
progeny, secondary to changes in endocrine function. The word “secondary” has sometimes 
been replaced by “consequent”. The existing evidence about endocrine disrupting activity is 
mostly related to chemicals that interfere with estrogenic or androgenic mechanisms, or that 
interfere with thyroid hormone function. Therefore the focus of this paper will be on these 
particular hormonal systems, but other hormones may turn out to be important in the future. 
Both in vivo (whole animal-based) and in vitro (non-whole animal based) tests are currently 
being proposed for the testing of endocrine disrupting activity.  Animal tests are justified on 
the basis that it is impossible to model the complex responses of the whole body to EDs, 
including biotransformation.  To date, there is still little or no experience with incorporating 
metabolic and toxicokinetic aspects into in vitro tests for EDs. This is a situation in sharp 
contrast to other areas of toxicity testing such as the genotoxicity area where in vitro tests are 
routinely conducted with and without metabolic capacity. This Detailed Review Paper aims 
to justify why in vitro assays for EDs should incorporate mammalian metabolising systems 
and to indicate how this could be done.  The  proper tests to detect EDs are still being 
developed or being validated, and tests that can predict the influence of chemicals on 
metabolism of endogenous or exogenous substances, or the influence of metabolism of a 
chemical on its ultimate effect, are not yet accepted for general use either. Therefore it will 
be difficult at present to incorporate measurements of metabolism into in vitro testing for 
endocrine disruption within the context of validated tests. However, some existing tests that 
take metabolism into account could perhaps already be used to prioritize substances for 
further testing.  
 
The background to ED testing, the available test methods, and the role of mammalian 
metabolism in the activation and the inactivation of both endogenous and exogenous steroids   6 
is described. The available types of metabolising systems are compared, and the potential 
problems in incorporating metabolising systems in in vitro tests for EDs, and how these 
might be overcome, are discussed.  Lastly, some recommendations for future activities are 
made. 
 
EDs act by a diversity of mechanisms including receptor binding, altered post-receptor 
activation, altered hormone synthesis, hormone storage, and release, clearance and 
perturbation of homeostasis. The main in vitro tests for EDs comprise subcellular hormone 
receptor ligand binding, the induction of proliferation (mitogenesis) in hormone-responsive 
mammalian cell lines, and transactivation systems in yeast and mammalian cell lines. The 
latter systems involve genetically-engineered cells which carry DNA sequences for 
mammalian hormone receptors, in conjunction with the respective response elements linked 
to promoter regions, together with the reporter gene itself. For the time being, ICCVAM has 
recommended not using yeast based assays or proliferation assays for ED testing because of 
potential problems with the penetration of substances through the cell wall and because it is 
not possible to observe the differences between agonists and antagonists. However, there is 
also a wealth of ED data generated by these systems in the public domain that, with 
normalization, might be usefully incorporated into multivariate and (Quantitative) Structure 
Activity Relationships ((Q)SAR) ED analyses. Furthermore, it might be worthwhile to 
investigate the possibilities to incorporate metabolic capacity in this type of cells by genetic 
engineering techniques and to determine the characterisation and intrinsic metabolic capacity 
of the cells used in proliferation and transfection assays. 
 
It is well-established that information on the metabolism of a substance is important in the 
evaluation of its toxic potential. Such metabolism occurs especially in the liver, but also in 
extrahepatic tissues, and is divided into phases I and II. The former involves the mixed 
function oxidase activities of the many isoforms of the cytochrome P450 (CYP) family of 
enzymes. Phase II metabolism involves the conjugation of metabolites generated by 
oxidation reactions in Phase I to water soluble entities.  In extra-hepatic tissues, the 
prostaglandin H synthase system is particularly active and causes the oxidation of a wide   7 
range of xenobiotics. In addition, metabolism by certain mixed function oxidases must also 
be considered in extra-hepatic tissue (Bernauer et al., 1999; 2000; 2002; 2003a) and it has to 
be taken into consideration, that extrahepatic metabolism may differ from hepatic 
metabolism. Metabolising systems for use in vitro can be either subcellular (enzyme 
homogenates, cytosol, microsomes) or cellular (the residual metabolism of the indicator cells 
themselves, metabolically competent primary cells or genetically-engineered cell lines). 
Despite the fact that there are several technical problems with using sub-cellular 
metabolising systems in assays for testing EDs (such as non-specific binding to protein, 
potential toxicity to target cells), there is sufficient evidence in the literature to show that 
these limitations can be overcome, and that the presence of such enzymes can modulate the 
chemical toxicity of several types of EDs. 
 
An initial recommendation is that future testing should first aim at determining whether a 
substance is likely to be systemically available, with special attention to the oral absorption 
in neonates. The use of (Q)SAR and (Quantitative) Structural Property Relationships 
((Q)SPR) to select chemicals that may have ED effects and/or that could be metabolised or 
interfere with metabolism of endogenous and exogenous substances should be explored. 
 
There is a good deal of information showing that endogenous steroids are extensively 
metabolised by phase I and II enzymes in both the liver and their target tissues, and that such 
metabolism can lead to the inactivation of steroids. In the case of endogenous steroids such 
reactions will affect their abilities to perform their normal functions. Obviously exogenous 
compounds that interfere with the inactivation of natural hormones can thereby cause 
endocrine disrupting effects. 
 
Inadequate incorporation of metabolism into in vitro tests for endocrine disruption could 
give rise to false positive data (due to lack of detoxification) or false negative data (due to 
lack of bioactivation) arising from the use of the tests. As yet, there is little information on 
the intrinsic metabolising potential of cell systems traditionally used to detect EDs. It is 
recommended to obtain this information as quickly as possible. No cell line is available at   8 
present that is genetically-engineered to express phase I, II or I and II enzymes 
simultaneously with molecular targets for detection of ED activity. While examples of such 
cell constructs are known to be currently under development by at least two different 
research groups (Elcombe C., and Lichtenberg-Fraté H., personal communications), it is 
suggested to start a feasibility study into the generation of genetically-engineered 
mammalian and yeast cell lines containing steroid hormone nuclear receptors, their response 
elements and reporter genes, together with genes expressing both phase I and II metabolising 
enzymes now.  Such cell lines expressing multiple molecular entities may have the 
advantage that there will be less binding to exogenous protein than might be the case when 
utilizing enzyme fractions, and furthermore, metabolites formed may not need to be 
transported from their sites of formation to intracellular targets. Recent developments with 
cytochrome P450 and receptor insertion into genetically modified yeast cell lines also show 
promise (Lichtenberg-Fraté H., personal communication, and Siervernich et al 2004). If 
these developments are confirmed, they should be developed into tests that can be used for 
regulatory purposes. 
 
It is further recommended that there should be an assessment of the intrinsic metabolising 
capacity of cell systems used in tests for EDs and an investigation into the relevance of using 
the prostaglandin H synthase (PHS) system and other, non-cytochrome P450 dependent 
enzymes, for metabolism of EDs. 
 
Much could be learned from the areas where metabolism is already incorporated like 
genotoxicity testing and the testing of cosmetics to design tests that could combine the 
assessment of endocrine effects and metabolism effects. Possibilities to make quick progress 
are to incorporate an S9 fraction into the in vitro tests for endocrine disruption, as is the case 
for genotoxicity and mutagenicity testing and to explore the possibilities to make use of the 
tiered approach that was proposed for the testing of cosmetics. The use of these methods in 
ED screening assays would imply that the potential toxicity that S9 could cause to target 
cells and the problem of potential protein binding need to be carefully addressed and well 
controlled.   9 
 
It is concluded that there is no justification for metabolism to be excluded from in vitro tests 
for EDs, and the perceived difficulties of incorporating metabolism into in vitro tests for 
EDs should not deter more research into how this can be achieved. The development and 
validation of these in vitro assays in conjunction with appropriate metabolising systems 
should be a matter of urgency. For the time being, a framework is proposed in order to 
incorporate already as much as possible the testing of endocrine disrupting activity coupled 
to assessment of the role played by metabolism in vitro, while tests are still being 
standardised and validated. The tests for ED targets and for metabolism can be developed 
and validated separately, but it is advisable that from the early phases on, attention is given 
to the fact that they ultimately may need to be combined.   10 
 
1. Endocrine  disruption 
1.1 Introduction 
It is widely believed that exposure to natural and synthetic chemicals in the environment, 
with potential to interfere with the endocrine system, may elicit a wide range of toxic effects 
in wild-life and in humans, in particular on the reproductive system and with respect to the 
induction of cancer (Atterwill & Flack, 1992, Neubert, 1997; McLachlan 2001; Baker, 2002; 
Eertmans et al., 2003). Such chemicals are termed endocrine disruptors (EDs). Different 
definitions for EDs have been proposed but one that is widely accepted was given at a 
conference in Weybridge (1996): “An endocrine disruptor is an exogenous substance that 
causes adverse health effects in an intact organism, or its progeny, secondary to changes in 
endocrine function. The word “secondary” has sometimes been replaced by “consequent”. 
Recently, interest has focused on exogenous substances, which have come to be called 
endocrine disruptors (EDs), which are thought to induce sex steroid-like effects (Harvey et 
al., 1999). Some of these chemicals are structurally-related to endogenous steroids while 
others are not (McLachlan. 2001). Endogenous sex steroid hormones, such as estrogen, 
testosterone and progesterone are a class of chemicals characterised by the presence of a 4-
ringed nucleus possessing high lipid solubility. Other related substances include the 
corticosteroids, mineralocorticoids, vitamin D and retinoic acid. Although the D vitamins are 
not steroids, all these substances are known to act on nuclear receptors of the same 
superfamily. Also thyroid hormone is known to act on nuclear receptors that belong to the 
same superfamily although they are structurally different from the steroid hormones (Orti 
1992; Graham and Clarke 1997, McLachlan 2001; Nilsson et al. 2001).  
Up to now most attention with regard to endocrine disruption has until now been focused 
upon sex steroid hormones and thyroid hormone because most evidence for such activity has 
been produced in these domains and as a consequence also tests have been made available 
that focus on these targets (EDSTAC 1998). There is no reason why other hormones like 
other steroid hormones, Follicle Stimulating Hormone (FSH), Luteinising Hormone (LH), 
insulin, insulin like growth factors, growth hormone etc., could not be affected by exogenous   11 
chemicals. Although it may be advisable to explore these possibilities, at present it seems to 
be premature to include them in a screening strategy with regulatory implications. This 
Detailed Review Paper will therefore focus attention to the hormones for which there is 
currently evidence that they are affected by xenobiotics. The mechanisms that may be 
involved include: 
•   specific binding to one or more members of an extensive family of hormone nuclear 
receptors (NRs) 
•   interaction with hormone receptors or hormone mediated transcription 
•   inhibition of steroidogenic enzymes 
•   chemically induced inhibition or induction of hormone metabolism 
•   other mechanisms. 
 
Legislation in the USA requires the testing of chemicals for endocrine activity (the Food 
Quality Protection Act of 1996, Public Law 104-170, and Safe Drinking Water Act 
Amendments of 1996, Public Law 104-182; Anon, 2001a). Other regions of the world, 
especially Japan and Europe, are also introducing or discussing legislation for ED testing 
(see e.g. Anon, 2001b). The specific testing of chemicals for ED activity may be 
incorporated into the new REACH legislation being developed by the EC (Combes et al., 
2003), although at present endocrine disruption is considered by the European Union as a 
mechanism that could have an impact on endpoints in general toxicology testing and not as 
an endpoint in its own right. 
 
In the USA, the EPA was charged with developing and validating a testing strategy for EDs. 
For this purpose, the EPA established an Endocrine Disruptors Screening and Testing 
Advisory Committee (EDSTAC) to consider possible testing strategies for EDs.  EDSTAC 
concluded that there is a need to include both in vitro and in vivo assays in a tiered approach. 
The proposed Tier 1 screening phase comprises both in vitro and in vivo assays, aimed 
primarily at detecting chemicals with endocrine activity and thus potential human health 
effects.  Among the recommended in vitro assays included in the battery are cell-free 
receptor binding, transcriptional activation, steroidogenesis in testis or Leydig cell cultures   12 
(despite reservations expressed about this particular assay), and frog metamorphosis. The 
Tier 2 test battery solely consists of in vivo assays, and includes two generation reproductive 
mammalian tests, as well as tests for environmental effects on target wild-life species.  It is 
intended that the Tier 2 battery will provide the definitive data on EDs suitable for risk 
assessment purposes.   
 
An OECD Working Group on Endocrine Disruptor Testing and Assessment (EDTA) has 
been established to define tests for validation.  As part of this activity, the OECD, in 
conjunction with the US Environmental Protection Agency (EPA), has become directly 
involved in validation programs for new animal tests (Combes and Balls, 2003).  For this 
purpose, the OECD has established a group to manage the validation of three new animal 
methods for the detection of EDs, namely, a uterotrophic assay for estrogens and anti-
estrogens, the Hershberger test for androgens and anti-androgens, and an enhanced 407 
protocol for repeat dose toxicity to detect agents acting via these and other mechanisms, such 
as steroidogenesis. While the development, standardization and validation of in vitro tests to 
detect endocrine disrupting activity is in progress and Detailed Review Papers on 
steroidogenesis and aromatase activity are being drafted, the Validation Management Group 
for non-animal tests within the EDTA has expressed concern that metabolism of xenobiotics 
is not yet considered for incorporation into the in vitro tests that will be used in the future 
and in particular with regard to endocrine disruption. In preparing an effort to combine 
metabolism and ED screening, the aim of the present Detailed Review Paper is to review the 
available evidence and to suggest possibilities to reach this goal. The methods for in vitro 
measurement of metabolism still need a lot of development, standardization and validation. 
ECVAM has addressed the issue with regard to cosmetics and has also held a workshop to 
review the possibilities for in vitro testing of metabolism in a more general context. These 
efforts generated much information that is also relevant to endocrine disruption testing in 
vitro and hopefully the research resulting from these workshops will solve a lot of the 
existing shortcomings with regard to endocrine disruptor testing. 
This DRP paper will especially focus on introducing metabolic competence into the in vitro 
test design. But testing for endocrine disruption has to be considered, as with all potency   13 
tests which will be used in hazard and risk assessment, to be a building block in an overall 
biokinetic evaluation of the endocrine disrupting potency. 
Biokinetic processes, like absorption, distribution, biotransformation and excretion, 
determine the relation of the administered and the internal dose. For in vivo animal studies, 
regulatory toxicokinetic studies determine the relation between the administered dose via the 
oral, dermal or inhalation route and the internal dose. When carrying out in vitro studies the 
same biokinetic information will be crucial to relate the administered in vitro dose to the 
internal dose (i.e. free concentration) reaching the cellular targets. Furthermore, it will be 
essential to relate the in vitro dose-regime and the bioavailability of the parent compound 
and its possible metabolites to a relevant dose in vivo. Therefore, the existing in vivo studies 
on ED compounds will be important to obtain realistic in vitro experimental designs for 
determining ED potency. 
A tiered approach is recommended to be followed in order to obtain all the necessary 
information to conduct a hazard and risk assessment, based on in silico and in vitro data sets. 
For any compound, information is needed on its likelihood to be systemically available, 
depending on the route of exposure. Furthermore, once entered into the system, the 
compounds’ distribution and also their biotransformations have to be evaluated. Once 
physiologically-based biokinetic models have been developed for the specific purpose to be 
used in a regulatory context, predictions will be possible concerning target system and target 
organ distribution of compounds and the importance of biotransformation aspects. 
 
The intention of this DRP is not to duplicate the work that is already being done in the 
development and validation of tests for endocrine disruption (ICCVAM 2003), and also 
being conducted by ECVAM, or for kinetics and metabolism of chemicals (ECVAM 2003, 
2004) separately, but rather to offer a framework to bring the two approaches together. 
Although interference of chemicals with steroidogenic enzymes and aromatase may be a 
major pathway towards ED activity, this will not be dealt with in detail because they are 
already the subject of a separate DRP at the OECD. 
   14 
A frequently mentioned hypothesis with regard to environmental contaminants and in 
particular EDs, is the possibility that low concentrations of different chemicals (which may 
not be effective alone) may interact, resulting in additive (Silva et al. 2002) or even 
synergistic effects. However, although it is realistic to assume that exposure to mixtures is 
what happens in everyday life, it would be out of the scope of this DRP to address the 
question how metabolism could be incorporated in in vitro models to study the action of 
mixtures. Indeed the incorporation of metabolic capacity into tests to evaluate single 
chemicals is complex in itself and adding a further degree of complexity at this stage does 
not seem to increase the chances of developing and validating new tests quickly. It would 
also not be obvious to decide which mixture of chemicals is actually going to mimic real 
exposures best, because infinite variations are possible. Furthermore, the tests that need to be 
developed will be used to investigate single compounds for regulatory purposes. It is 
therefore considered as a first priority to develop methods that would allow the study of 
single chemicals. 
 
1.2  Mode of action of EDs 
EDs act by a diversity of mechanisms including receptor binding, altered post-receptor 
activation, altered steroidogenesis (modulation of hormone synthesis), perturbation of 
hormone storage, release, clearance and homeostasis. The immediate effects of these 
activities, depending on the nature of the ED can be for instance: estrogen agonism or 
antagonism, androgen agonism or antagonism, suppression or induction of levels of other 
endogenous hormones, such as the release of FSH, LH or prolactin, or other effects that are 
the consequence of these changes. 
 
Since many mechanisms exist through which EDs can exert an estrogenic or androgenic 
agonist effect, the terms estrogenic/anti-estrogenic or androgenic/anti-androgenic do not 
always have the same meaning when used in the literature. Usually estrogenic or androgenic 
means that a chemical has the same effect as 17β -estradiol or testosterone or another 
recognised natural or synthetic agonist acting at the ER or AR in a particular system. Anti-
estrogenic or anti-androgenic means that a substance prevents 17β -estradiol or testosterone   15 
or another recognised natural or synthetic agonist acting at the ER or AR from exerting its 
effect in a particular model. 
 
The effects mentioned above are mediated in part by binding specifically to an extensive 
family of nuclear receptors (steroid hormone receptors or SHRs; Warner et al., 1999). SHRs 
have structural features in common which include a central highly-conserved DNA binding 
domain that targets the receptor to specific DNA sequences (hormone response elements, 
HREs). The terminal portion of the receptor includes a ligand binding domain that interacts 
directly with the hormone. This domain contains a hormone-dependent transcriptional 
activation region.  Binding of the steroid hormone to the receptor protein causes it to 
undergo a conformational change resulting in binding of the DNA to the HRE to form a 
complex that triggers or suppresses the transcription of a specific set of genes (Hornhardt 
and Wiebel 1996; Wiegel, 1996; Jacobs and Lewis, 2002; Nilsson, 2001 and Combes, 
2000a).  
 
The estrogen receptor (ER) exists in at least 2 subtypes, termed α  (the first discovered) and 
β, and each of these is encoded by a separate gene (Orti et al. 1992; Graham and Clarke 
1997, McLachlan 2001; Nilsson et al. 2001). These ER subtypes differ in their tissue 
distribution and relative ligand binding affinities for the same hormones (a fact that could 
account for differential hormonal effects depending on the tissue) and also appear to have 
complementary but different functions (reviewed in Jacobs 2005).  ERβ, has been shown to 
be antiproliferative when present along with ERα in breast cancer cells (Paruthiyil et al. 
2004), although the role of ERβ in breast cancer is unclear. It should be noted that apart 
from these two nuclear receptors there has been identification of  a γ subtype in teleosts 
that appears to have evolved from ERβ gene duplication and may mediate some effects of 
EDs in these fish (Hawkins et al. 2000; Hawkins and Thomas 2004). Furthermore, there is 
an estrogen receptor that is located in the cell membrane which is responsible for the fast 
non-genomic  responses to the hormone (McEwen and Alves 1999; Belcher and 
Zsarnovsky 2001; Matthews and Gustafsson 2003; Hasbi et al. 2005). While the ER 
located in the cell membrane seems to be structurally related to the nuclear ERs, they can   16 
also be activated by larger molecules that are unable to enter the nucleus and bind with the 
nuclear ERs (Harrington et al 2005). However, the possibility that cofactors or the 
immediate surroundings of the receptor may influence binding affinity differently, that 
signal transduction mechanisms coupled to membrane receptors can be affected by 
chemicals in a different way from the NRs, and the fact that chemicals that do not easily 
penetrate into cells can reach the membrane receptors, may need to be taken into account. 
Most studies have been directed to the α sub-form of the ER, and therefore combined 
assessments of metabolism and interference with estrogenic mechanisms should include 
this subtype. ERα stimulates a classic estrogenic response; ERβ modifies this by altering 
the recruitment of c-Fos and c-Jun to estrogen responsive promoters (Matthews et al. 
2006). Currently ERα is the ER being (pre) validated for ER binding and activation hazard 
assessment screening procedures, but whether addressing only ERα binding is sufficient for 
regulatory screening purposes requires further investigation. 
A similar binding affinity was for instance suggested by one study with a selection of 
industrial chemicals but this was not confirmed in the same study with phytoestrogens 
(Kuiper et al. 1998) and several later studies have confirmed the selectivity of  
phytochemicals and their metabolites for ERβ (e.g. De Angelis et al 2005)  . In particular 
with regard to the efficacy to induce effects, but also perhaps with regard to ligand binding 
affinity, substances can behave differently on both subtypes (Barkhem et al. 1998). 
Metabolic competence may need to be included in all ER-related in vitro tests that will 
ultimately be deemed necessary for ED testing. 
 
The interest in thyroid hormone has arisen because it plays a role in the control of 
development (e.g. metamorphosis in amphibians and brain development in mammals), and 
chemicals may alter its synthesis, transport and catabolism (Capen 1997; Cheek et al. 1999; 
Craft et al. 2002; DeVito et al. 1999; Fowles et al. 1994; Howdeshell 2002; Kato et al. 2000; 
Zhou et al. 2001). Interference by xenobiotics with the turnover over the thyroid hormone 
may at present seem to be a more important mechanism for causing endocrine disruption 
than interactions at the thyroid receptor level. However, PCB’s may interfere with the 
thyroid receptor function and some of these chemicals seem to suppress transcription that is   17 
linked to thyroid receptor activation (Miyazaki et al. 2004; Fritsche et al. 2005). Thyroid 
receptor binding assays or transactivation assays incorporating metabolism may therefore be 
needed. Different thyroid hormone receptors were described (Lazar 1993; Yen 2001) and the 
question which of them needs to be used in binding or transactivation assays may need to be 
addressed sooner or later. With regard to the androgen receptor, the issue of different 
subtypes to be tested does not exist at present. 
 
The Aryl hydrocarbon receptor (AhR) is also involved in modulating the effects of retinoids 
(Soprano and Soprano 2003), estradiol and dexamethasone (Lai et al. 2003) or progesterone 
(Kuil et al. 1998). Thus, a mouse hepatoma cell line (Hepa1c1c7) possessing this receptor, in 
conjunction with a dioxin response element and a luciferase reporter gene complex, was 
shown to respond to chemicals with dioxin-like activity in pulp-mill effluents (Zacharewski 
et al., 1995). The AhR, a member of the PAS (Per-Arnt-Sim) family of nuclear regulatory 
basic helix-loop-helix proteins, has been detected in nearly all vertebrate groups examined 
(Hahn 1998; Hahn 2002; Kato et al. 2002) and appears to have a fundamental role in cellular 
physiology, neurodevelopment and circadian rhythmicity (Poellinger 2000). Upon ligand 
binding the receptor dissociates from heat shock protein with which it forms a complex in 
the cytosol, it enters the nucleus and joins with the heterodimeric partner AhR Nuclear 
Translocator ARNT (Kato et al. 2002). Predominantly found in hepatocytes, but also in 
breast cancer cells (Nguyen et al. 1999), and the lung (Song et al. 2002), this AhR/ARNT 
dimer interacts with the Dioxin Response Elements (DRE) on the DNA, resulting in ligand 
dependent  transcription of CYP1A1, CYP1A2, CYP1B1, the glutathione S-transferase 
subunit Ya, quinone oxidoreductase, UDP-glucuronosyltransferase and aldehyde-3-
dehydrogenase (Kato et al.2002). If chemicals interfere with the activity of the AhR, they 
may thus have effects on metabolism of xenobiotics, including these chemicals themselves, 
and on the concentration of steroid hormones, which would lead to endocrine effects. For 
instance the in vitro antiestrogenic activity in MCF-7 breast tumor cells caused by 2,3,7,8-
tetrachlorodibenzo-p-dioxin is explained by enhanced metabolism of estradiol through this 
pathway (Spink et al. 1990). ER-mediated estrogen signalling may also be modulated by a 
co-regulatory-like function of activated AhR/ARNT, giving rise to adverse estrogen-related   18 
actions of dioxin-type contaminants (Ohtake et al. 2003). Such a complex mechanism may 
be extremely difficult to investigate in vitro, but a simple Ah receptor assay may be able to 
pinpoint a number of chemicals that need further investigation with respect to interference 
with metabolism. 
 
1.3  The need for in vitro tests for EDs 
Animal tests for detecting endocrine disruptors are necessarily detailed, since many 
mechanisms can be involved in the perturbation of the complex hormonal systems of 
mammals, and there are subtle inter-species differences in the ways these work and the 
consequences in terms of physiology, reproduction and development (Zacharewski, 1998). 
This means that the validation of these assays needs very careful consideration (Ashby, 
2000).   
 
The EDSTAC Tier I testing scheme requires that both in vitro and in vivo screens should be 
developed, and it is essential that the former test methods are developed and validated so 
that they can be used first in the test battery for prioritizing chemicals for further testing and 
also to facilitate the interpretation of data from animal tests. 
 
From an animal welfare point of view, potentially very large numbers of animals will be 
required for endocrine disruptor testing, should the current EPA proposals go ahead. The 
actual numbers will depend on the sensitivity and specificity of the testing methods that will 
be used (Purchase, 1999).  The use of animals is morally controversial, and often more time-
consuming and costly than using non-animal approaches. The reduction of animal testing is 
an important reason to develop and validate in vitro models for testing EDs that include 
metabolism of the chemicals to be tested. 
 
1.4  In vitro tests for endocrine disruptors 
 
There have been several studies on the structure-activity of EDs (e.g. reviewed in Combes, 
2000; Benfenati E  et al. unpublished review report for  the European Chemicals Bureau,   19 
European Commission, December 2005) most of which have been conducted for the ERα. In 
summary it appears that many natural and synthetic estrogens, generally have in common the 
phenolic OH group on a small lipophilic molecule of about 200 - 300 Daltons. However, the 
OH substituent is not essential for ER mediated activity. There is a large diversity of 
potential EDs and many possible molecular targets through which they might act The 
possibility that (Q)SARs may be used to determine which chemicals are most likely to have 
endocrine disrupting effects is being further explored, and some progress has been reported 
recently notably with regard to AhR, ER, PXR and AR (e.g. Jacobs, 2004; Vedani et al 
2005). A question also to be answered is how they could be used in conjunction with 
(Q)SARs that aim at predicting metabolism of chemicals. 
 
The main in vitro tests for endocrine disruption comprise subcellular hormone receptor 
ligand binding, the induction of proliferation (mitogenesis) in hormone-responsive 
mammalian cell lines, and transactivation systems in yeast and mammalian cell lines. While 
most of the available tests at present are related to ER or androgen receptor (AR) activation, 
the question whether other hormone receptors also need to be examined can be raised. 
Therefore an ideal test that combines assessment of metabolism and of hormonal action 
should be easily adaptable to new endocrine targets that may become relevant and available 
for testing in the future. 
 
Many subcellular, in vitro and animal tests have been listed in a compendium of methods for 
detecting EDs (Anon, 1996a), and such methods have been the subject of several reviews 
(see for some examples Table 1; see further Reel et al., 1996; Holmes et al., 1998; Eertmans 
et al., 2003). An extensive evaluation and discussion of ED tests in vitro is presented 
elsewhere (NICEATM 2002a,b,c,d; ICCVAM 2003). Prevalidation of estrogen-binding, 
androgen-binding, estrogen and anti-estrogen transcriptional tests, androgen and anti-
androgenic transcriptional tests is also underway at ECVAM. At present, several in-vitro 
assays that aim to detect endocrine disruptor activity are being considered at the level of the 
OECD. These include receptor binding assays based on GST-fused human ER, ligand 
binding domain expressed in E. Coli, MBP-fused human androgen receptor ligand binding 
domain expressed in E. Coli, rat uterine cytosol ER, rat prostate cytosol androgen receptors,   20 
PanVera hrERα  and PanVera rAR. Transcriptional activation assays with human or rat ER 
of both subtypes and human AR are also being investigated. Some of them exhibit stable 
receptor expression while others exhibit transient receptor expression. Examples are an 
MDA-kb2 cell line expressing AR, BG-1 cells stably transfected with estrogen-responsive 
luciferase reporter gene that express human ER, three hrERα  binding assays (PanVera, Jena 
Biosciences and CERI) and ER-Calux, MELN, AR-Calux and PALM based on two human 
breast cancer cell lines, a bone cell line and a prostate adenocarcinoma cell line respectively. 
In order to better standardise the tests on the one hand and to make use of the possible 
intrinsic metabolism in these cell lines on the other, knowledge of the intrinsic metabolic 
capacity present in the cell lines considered for validation will be useful. Perhaps the 
presence of intrinsic metabolism may be one of the contributory factors for the ultimate test 
selection for the validation stage. 
 
1.4.1  In vitro receptor binding assays  
These assays provide a relatively rapid means of quantifying the ability of chemicals to bind 
to the ERs and AR particularly, and to competitively inhibit the binding of standard ligand 
(see Häggblad et al., 1995).  Theoretically they should even allow high throughput screening 
technology to be used, but this remains to be determined certainly if one would want to 
combine it with tests for metabolism. With regard to the ERs, the subtype that is being 
investigated is mostly the α -subtype. The assays involve assessing the molecular binding of 
the hormone to isolated and purified receptor protein. Competitive ligand binding assays, 
whether alone or combined with reporter gene expression, are designed to detect chemicals 
that directly interact with the NRs (Gray et al., 1997). A further question that needs 
addressing is whether one (e.g. ER β) of the other subtypes of ERs should be incorporated in 
a test scheme. The AR and thyroid receptors have been proposed for inclusion into the 
screening for endocrine disruptors by EDSTAC. Mere ligand binding interaction studies 
cannot distinguish between agonists and antagonists and therefore it is imperative to have a 
functional in vitro test available that could do so. If metabolism is included in functional 
tests, one should realize that the agonist that will be used to obtain the background 
activation, against which an antagonist effect of chemicals can be determined, may also be   21 
metabolised by the added metabolic enzymes. The development of functional tests for 
antagonism in the presence of metabolic competence of any kind will therefore require 
careful consideration of this problem. Substances like genistein and the medicinal products 
tamoxifen and raloxifene can behave as agonists, partial agonists or antagonists (Kauffman 
et al. 1997, Jordan and Morrow 1999, Dutertre and Smith 2000, Liu et al. 2003) depending 
on species, tissue and receptor examined. It would also be advisable to assure that the effects 
and nature of the binding interactions of such substances are precisely predicted by the tests 
to be developed. 
 
1.4.2  Induction of hormone-responsive mammalian cell proliferation 
Tests that are based on the induction of proliferation in estrogen-responding cells, 
particularly in the MCF-7 human breast cancer cell line, can be used to detect estrogenic 
activity (Fang et al. 2000; Ramamoorthy et al. 1997; Soto and Sonnenschein 2001). A 
sensitive reporter gene that uses green fluorescent protein expression, expressed in MCF-7 
cells, was also used to detect compounds with estrogenic activity (Miller et al. 2000). 
Metabolism may have an impact on the effect of endocrine disruptors since some of them 
may stimulate the formation of 16α -hydroxyestrone from 17β -estradiol in MCF-7 cells 
(Miyamoto and Klein 1998). While the former is still estrogenic, it is also capable of 
damaging DNA. Although sometimes questioned, it is often considered as a possible 
biomarker of breast cancer, particularly in conjunction with other hydroxylated metabolites 
(Castagnetta et al. 2002, Ursin et al. 2002, Alvarez-Vasquez et al. 2003, and Fowke et al 
2003). It may influence the cell cycle and proliferative responses of MCF-7cells (Lewis et al. 
2001, 2005). Such an effect would then be attributable to an effect on estrogen metabolism 
rather than mediated by metabolism of the xenobiotic per se, but mutual interference 
between metabolism of endogenous hormones and xenobiotics should not be excluded. 
Proliferation assays are not recommended by ICCVAM because cell proliferation can be 
mediated through pathways other than those involving transcriptional activation of estrogen 
responsive genes (ICCVAM 2003). On the other hand, this could have the advantage of 
detecting endocrine disrupting mechanisms that are not mediated by an interaction with the   22 
receptor, and if the cell line used would have also intrinsic metabolic capacity, the potential 
advantages may outweigh the possible shortcomings. 
1.4.3  Transactivation assays (hormone-sensitive transcription of reporter genes) 
These tests are based on the development of genetically engineered mammalian cells or 
strains of yeast (Saccharomyces cerevisiae) (Balaguer et al. 1996; Fang et al. 2000; 
Ramamoorthy et al. 1997).  The cells have been transformed (or transfected) by introducing 
vectors bearing DNA sequences for human or mammalian ER NRs, in conjunction with the 
respective responsive elements linked to promoter regions for a reporter gene, together with 
the reporter gene itself. The transfected NR can function as a steroid-dependent, 
transcriptional activator.  The induction of transcription of the reporter gene can be readily 
detected and quantified, (for example, colorimetrically, by using a suitable substrate [Joyeux 
et al., 1997]). Receptor activation by a test chemical is detected as a stimulation of reporter 
gene expression following interaction with the response element.  Reporter genes can be 
introduced into cells just for the duration of the experiment (transient transfection), or 
permanently, by developing a genetically altered and new cell-line (stable transfection).  
Yeast-based assays are not recommended by  ICCVAM because many substances are poorly 
transported through the yeast cell wall (ICCVAM 2003). However  a strain of genetically 
modified yeast (Saccharomyces cerevisiae) cells have been modified with respect to deletion 
of drug resistance transporters to overcome this problem (Sievernich et al 2004), and are 
currently being developed further   for receptors and P450 enzymes  in addition to hERα 
(Lichtenberg-Fraté personal communication) . It has also been suggested that another 
disadvantage of yeast-based assays is that they may not allow differentiating between 
agonists and antagonists (Dudley et al. 2000; Kohno et al. 1994, Legler et al. 2002b; 
ICCVAM 2003). Again, this problem can be overcome, this time  by adaptations of plate 
designs (Kamp et al 2005), and on the whole the data generated from a relatively low cost 
and easy to use system, does appear to be highly consistent with literature data. Use of the 
yeast estrogen screen as part of a testing battery may therefore be of value. Mammalian 
transactivation systems involve the use of luciferase, GFP, galactosidase or CAT reporter 
genes. For instance, Rogers and Denison (2000) have developed a stably transfected human 
ovarian cell line (BG1), using the luciferase gene as a reporter gene, for the detection of   23 
estrogenic and anti-estrogenic chemicals. Similarly  293 HEK cells can be transfected with 
ERβ receptors (Lemmen et al. 2002; Meerts at al. 2001). Transactivation assays have also 
been generated that make use of endogenous receptors, such as the human breast cancer cell 
line-derived MVLN (Demirpence et al., 1992; Freyberger and Schmuck 2005) and ER 
CALUX (Legler et al, 1999) assay, using MCF7 and T47D cells, respectively. Interestingly, 
ER CALUX cells have been used in combination with S9 (Legler et al. 2002a, b). 
 
2. Metabolism 
2.1  The role of metabolism in the activation and detoxification of 
xenobiotics: Phase I and Phase II metabolism 
  
Information on the metabolism of a substance is important in the evaluation of its toxic 
potential. For example, the determination of metabolic stability can provide information on 
the potential for bioaccumulation and whether a chemical is likely to be converted to a more 
active form (metabolic activation) or a less active form (metabolic detoxification). With 
regard to endocrine disruptors, one should take into account that metabolism of the 
xenobiotic may not only alter its own potency by creating metabolites that are either more or 
less active than the parent compound. Hormones and in particular steroid hormones are 
formed or metabolised by enzymes that participate in the metabolism of xenobiotics. 
Prominent examples of such enzymes are the cytochromes P450 (CYPs). A chemical that is 
metabolised by these enzymes may, by mere interaction with the enzyme, act as a competitor 
for the hormone or hormone precursor and therefore disturb hormone levels and hormonal 
equilibrium. 
 
A substance that is absorbed orally from the gastrointestinal tract is transported via the portal 
circulation to the liver, where it may be subjected to hepatic metabolism, followed by 
elimination in the bile or via the kidneys. There is also the possibility of extra-hepatic 
metabolism.  
A typical chemical metabolism pathway involves the oxidation of the parent substance 
(phase I oxidation), followed by conjugation of the oxidised moiety with highly polar   24 
molecules, such as glucose, sulphate, methionine, cysteine, glutathione or glucuronic acid 
(phase II conjugation). The key enzymes for phase I oxidation are the isoforms of the CYP 
family of enzymes. The superfamily of CYPs are heme-containing enzymes with very wide 
substrate specificities by virtue of their existence in a large number of isoforms or isozymes.  
CYP enzymes can often be induced or inhibited by exogenous chemicals that may exert 
endocrine effects through this mechanism. While the liver is the main site of xenobiotic 
metabolism, phase I and II metabolism also occurs in most tissues including the gut 
microflora (Combes, 1992, Coecke et al., 2006). 
 
Interactions between different EDs are generally considered a major issue. One possibility 
for EDs to interact with each other may be at the level of enzyme induction or inhibition as 
is often the reason for drug-drug interactions (Lin and Lu 2001). Enzyme induction or 
inhibition is not only a possible means for chemicals to exert endocrine disruption but it can 
ultimately also alter the metabolism of the chemical itself. Inhibition of CYPs ( and thus risk 
for interactions) can be studied using incubations with microsomes or cell lines in 
combination with substrates specific for CYP isozymes or phase II enzymes in the absence 
and presence of EDs (Brandon et al. 2003, Tucker et al. 2001). By measuring the effect on 
the disappearance of the substrate, the inhibition capacity of the ED can be determined. The 
induction of CYPs by EDs can be investigated by measuring the binding to nuclear receptors 
constitutive androstane receptor (CAR) and pregnane X receptor (PXR) or the CYP mRNA 
levels (Xu et al. 2005, You 2004, Sparfel et al. 2003, Sonoda et al. 2003, Friedman et al. 
2002, Synold et al. 2001). Figure 1 indicates the principal NRs that induce key P450 
transcription factors for phase I metabolism of steroidal, xenobiotic and endocrine disrupting 
substances.   
Furthermore, the metabolism rate of a model substrate in cell lines pretreated with EDs can 
be determined (about 48 h is necessary for CYP induction) (Brandon et al. 2003, Tucker et 
al. 2001). Genetics (such as CYP polymorphisms), disease, diet, cigarette smoking, age and 
environmental factors may determine the induction or inhibition of CYPs (Lin and Lu 2001). 
This may mean that certain subgroups may be more susceptible than the general population. 
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CYPs catalyse mixed function oxidase activities by introducing oxygen into a molecule, 
thereby rendering it more polar. The major human CYPs involved in chemical metabolism 
are CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, 
CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP3A7 and CYP4A11 (Lewis, 1996; Clark, 
1998; Soucek, 1999; Masimirembwa et al., 1999; Ozawa et al., 2000; Tanaka et al, 2000; 
Riley et al., 2001; Sheweita, 2001; Nishimura et al., 2003; Furukawa et al., 2004; Lanza et 
al., 1999; Sheets et al., 2004; Ding and Kaminsky, 2003).  Some of these are mainly active in 
the fetal liver and not detectable in adults (see section 2.5). Of the different CYP enzymes, 
CYP3A4 is the most abundant in the human liver, and plays a key role in the metabolism of 
steroids and xenobiotics: metabolising more than 50% of all currently prescribed drugs. 
Polymorphisms and interindividual variability in the expression of these enzymes are a key 
reason why different individuals react differently to chemicals, and also a major reason for 
the wide range of experimental variability with tests based on human liver tissue(Lin and Lu 
2001). 
 
The key phase II enzymes include N-acetyl transferases (NAT), UDP-dependent 
glucuronosyl transferase (UGT), sulphotransferases (SULT), sulphatases, and glutathione S-
transferases (GST). The structures and functions of phase II enzymes have been reviewed 
elsewhere (Burchell et al., 1998; Glatt, 2000; MacGregor et al., 2001; Turan et al 2005). 
These enzymes catalyse the conjugation of the metabolites generated by phase 1 metabolism 
to water soluble moieties such as glucuronic acid and glutathione, which traps electrophilic 
intermediates.  However, although phase II metabolism is generally considered to be 
detoxifying, it can also generate powerful electrophiles that are highly reactive (Combes, 
1992).  The phase II enzymes can also conjugate certain groups in the parent compound 
without precedent phase I metabolism. This has been reported for instance for aromatic 
hydroxyl groups in beta-adrenergic agonists (Smith 1998) or for halogenated compounds 
(reviewed by Guengerich 2005). 
 The sulphation of estrogens and thyroid hormones by SULT enzymes and sulphatases 
respectively is a particularly important route for the removal of active hormones from the 
body.  In mammals SULT enzymes create a circulating pool of estrone sulfate that can be   26 
converted back to active estrogens in peripheral tissues. With respect to estrogen metabolism 
and ED impacts, ED chemicals such as bisphenol A, alkylphenols and phthalate plasticizer, 
as well as plant phytoestrogens, have been shown to inhibit the inactivation of estrogens via 
the major SULT isoforms: estrogen sulphotransferase (SULT1E) and phenol 
sulphotransferase (SULT1A1) (Nishiyama et al 2002,  Kirk et al. 2003;  Waring and Harris 
2005). As part of the series of  European Commission funded  research programmes, in vitro  
assays utilizing both primary human liver  and fish  liver tissue,  human neuronal (SK-N-
SH), gastrointestinal (HT-29) and medulloblastoma (TE 671) cell lines, all of which express  
SULT isoforms,  have been developed  for screening SULT  inhibition by Waring’s group, 
(Davies et al 2004; Harris et al. 2005; Kirk et al 2003;  Turan et al., 2005).   
These known indirect or non-genomic mechanisms indicate that the phase II metabolism 
may be of particular importance and must be investigated thoroughly in the context of in 
vitro ED testing.  
 
 
2.2  In vitro methods for the measurement of metabolism 
 
2.2.1  Current status of computer-based approaches for assessing metabolism 
A number of computer-based expert systems for predicting metabolism and metabolism-
dependent toxicity are undergoing development, and have been reviewed elsewhere 
(Dearden et al. 1995; Cronin, 2001). 
 
An example is the METEOR system, a rule-based system for the prediction of metabolism 
which is being developed by LHASA (Greene et al., 1999). METEOR consists of a 
knowledge base of biotransformations that describe the metabolic reactions catalysed by 
specific enzymes, and that are related to specific substrates. The system can be linked with 
DEREK, to provide a means of assessing both metabolism and toxicity.  
 
Two other rule-based expert systems, HazardExpert and MetabolExpert, are being developed 
and marketed by CompuDrug Chemistry Ltd. HazardExpert enables predictions to be made 
for a number of toxicological endpoints, taking into account factors such as species, dose, 
route and exposure duration. HazardExpert can be linked to MetabolExpert, which makes   27 
qualitative predictions of the metabolites of compounds. These predictions are made by 
using a rulebase consisting of molecular fragments. By linking HazardExpert with 
MetabolExpert, the user can obtain predictions of toxicity not only for the parent molecule, 
but also for the potential metabolites of the molecule. 
 
Recently, a new rule based approach has been developed where predicting the role of 
metabolism in selective toxicity and adverse health outcomes was associated with a 
probabilistic framework. Specific metabolism simulators have been developed for predicting 
biodegradation. CATABOL (Jaworska et al., 2002) is a tissue metabolism simulator. TIMES 
(Mekenyan et al., 2004a) uses a heuristic algorithm to generate plausible metabolic maps 
from a comprehensive library of biotransformations and abiotic reactions and estimates 
system-specific transformation probabilities. The transformation probabilities have been 
calibrated to specific reference conditions using transformation rate information from 
systematic testing or databases with observed (thermodynamically stable) metabolic 
products. The quantitative evaluation of transformation by their probabilities (plausibility 
estimates) allowed prioritisation of metabolites by their stability, reactivity, solubility, etc. 
The simulators have been combined with toxicity predicting tools allowing predicting 
metabolic activation of chemicals in integrated systems; thus, the TIMES system has been 
used to predict mutagenicity and skin sensitisation accounting for metabolism of chemicals 
(Mekenyan et al., 2004a; 2004b) 
 
Another approach to the prediction of metabolism (and metabolism-dependent toxicity) is 
provided by the Computer-Optimised Molecular Parametric Analysis of Chemical Toxicity 
(COMPACT) method of Lewis and coworkers (Lewis et al., 1998). This method can be used 
to predict whether a molecule has the potential to act as a substrate for one or more of the 
CYPs, or the ability to promote peroxisome proliferation. 
 
The COMPACT method is based upon the premise that there are certain structural 
requirements of a molecule that make it susceptible to oxidative metabolism. Firstly, 
molecules must be capable of binding to CYPs, due to their planar molecular shapes.   28 
Secondly, molecules that are capable of binding to a CYP must also be susceptible to 
chemical oxidation. The COMPACT approach is therefore based on two physicochemical 
descriptors, molecular planarity and electronic activation energy. Molecular planarity is a 
function of the cross-sectional area and molecular depth of the potential substrate, whereas 
the electronic activation energy is the difference between the energies of the highest 
occupied and lowest unoccupied molecular orbitals. A two-dimensional plot of molecular 
planarity and electronic activation energy for a series of molecules reveals that they can be 
divided into categories according to the particular CYP by which they are metabolised 
(Parke et al., 1990). 
 
The prediction rate obtained with the COMPACT system was found to be improved when 
its predictions were considered in combination with those generated by the HazardExpert 
system (Brown et al., 1994), demonstrating the usefulness of a battery approach to 
prediction. The COMPACT approach has been extended to include the molecular (protein) 
modelling of the CYP enzymes themselves (Lewis et al., 1999) and NRs (e.g. Jacobs et al 
2003). The use and potential of crystal structures and molecular modelling of NRs and 
CYPs, for validation as in silico alternative tools for hazard assessment, were examined 
more closely at an expert ECVAM Workshop on Molecular Modelling Approaches for 
Human Hazard Assessment of Chemicals in February 2006 (Jacobs et al., 2006 workshop 
report in preparation). 
 
Another computational method for predicting potential metabolites is the META system, 
which is part of a suite of programs developed by Klopman and colleagues (Klopman et al., 
1994; Talafous et al., 1994). The rules in the META rulebase were taken from the 
biochemical literature, rather than derived by a statistical approach. 
 
The large diversity of chemicals that might interfere with hormone function and the many 
potential molecular targets may make the establishment of (Q)SARs for EDs and for the 
potential to be metabolised or to affect metabolism of endogenous hormones or ED’s 
difficult but the possibility should and is being explored further. For instance the US EPA   29 
have recently initiated an international  chemical prioritization research project (ToxCast) 
that  aims to evaluate chemical properties and effects, including ED effects across a wide 
range of information domains. 
 
2.2.2  Types of metabolising systems applied to in vitro test systems 
A number of in vitro systems are available for studying metabolism. These include: 
precision-cut tissue slices, subcellular fractions such as the microsomal fraction, primary 
cells in suspension, primary monolayers of cells in culture, continuous cell lines, 
immortalized primary cells, liver-derived cell lines re-expressing biotransformation enzymes 
and genetically-engineered cell lines expressing biotransformation enzymes (Schmalix et al., 
1996; Clarke, 1998; Philip et al., 1999; Coecke et al., 1999, 2000; Bull et al., 2001). These in 
vitro tests can incorporate important toxicological endpoints, including cytotoxicity and 
genotoxicity. It would be worthwhile to investigate whether endocrine endpoints could also 
be expressed in these cell lines or whether proper indicator cells can be co-cultured in cell 
lines with metabolic capacity. The precision-cut tissue slices may be less useful from the 
technical point of view if they need to be combined with other cells or subcellular fractions, 
as indicators of effect, as will be required for simultaneous testing of metabolism and ED 
effects. 
 
To date, no in vitro methods for determining phase I or phase II biotransformation, or for 
evaluating metabolism-dependent toxicity, have been validated according to ECVAM’s 
principles and procedures. The current OECD Test Guideline 417 for assessing the 
toxicokinetic effects of chemicals (OECD, 1984) is based on in vivo studies. However, many 
studies provide support for the usefulness of in vitro methods for assessing metabolism and 
metabolism-dependent toxicity. From such studies, it is evident that there are enormous 
species differences in toxicokinetics; this is especially true for the metabolic differences 
between humans and rodents (Ozawa et al., 2000). Therefore, there is a great need for 
human-based in vitro models that would offer better predictions of potential hazard to 
humans than could ever be obtained from laboratory animal studies (Coecke et al., 1999, 
2000, 2001; Doehmer et al., 1999). The status of the currently available approaches for 
assessing metabolism is summarised in Table 2.   30 
 
Recently, there has been success in relating the rate of in vitro metabolism of several 
compounds with the corresponding events in vivo. This represents a major step, since the 
value of in vitro metabolism systems has traditionally been considered to be purely 
qualitative in nature. The basis of this relationship is the use of the parameter, intrinsic 
clearance, which is a pure measure of enzyme activity toward a chemical in vivo and is not 
influenced by other physiological determinants of clearance, such as hepatic blood flow or 
drug binding. The in vitro equivalent of this parameter is the Vmax:Km ratio. The utility of 
in vitro intrinsic clearance as a predictor of in vivo intrinsic clearance, and therefore hepatic 
clearance and total body clearance, has been assessed with a database of 35 drug substrates 
for rat CYPs (Houston & Carlile, 1997). Other studies have demonstrated the usefulness of 
the intrinsic clearance approach for predicting kinetics in humans (Obach et al., 1997; Ito et 
al., 1998). 
 
Subcellular systems are added to in vitro test systems as enzyme homogenates. Such 
homogenates can comprise: 
•   purified enzymes 
•   cytosolic soluble enzyme fractions (S100 supernatant) 
•   microsomal particulate enzyme fractions (S100 pellet) 
•   post-mitochondrial S9 supernatant (consisting of both cytosol and microsomes). 
All of these systems are capable of activating and/or detoxifying xenobiotics.   
 
In addition, the prostaglandin H synthase (PHS) system has been added exogenously to in 
vitro toxicity assays (Combes, 1992). This enzyme catalyses the first two steps in the 
synthesis of prostaglandin, thromboxane and prostacyclin.  Two forms of the enzyme have 
been characterised (PHS 1 and 2) and both are heme proteins that exhibit both 
cyclooxygenase and peroxidase activity, the latter being responsible for the one electron 
oxidation of a wide range of xenobiotics (Eling et al., 1990). The peroxidase activity of PHS 
can be activated in vitro if enzyme extracts are supplemented with arachidonic acid, and 
several chemicals are activated by the PHS system to mutagens and carcinogens (Woo et al.,   31 
1988; Flammang et al., 1989). Microsomes from ram seminal vesicles have been shown to 
have a high level of PHS activity. 
 
Cellular enzyme systems can also be used in in vitro assays, and these fall into one of three 
main categories: a) residual metabolism of the indicator cells; b) the use of co-culture 
systems comprising the indicator cells and a metabolically-competent cell line (e.g. freshly 
isolated hepatocytes or genetically-engineered cell lines); and c) the use of genetically-
engineered cell lines that simultaneously act as both indicators of toxicity and sources of 
metabolism. 
 
The contribution of the indicator cells themselves to metabolism, with or without the 
addition of exogenous metabolism is unavoidable and should not be overlooked when 
interpreting toxicity data (Combes, 1992).  In the case of residual metabolism, often the level 
and specificity is unknown and although it is usually assumed to be low its presence can 
complicate the situation.  To standardise the detection system to the largest possible extent it 
seems imperative to study the intrinsic metabolism in the indicator cells that will be used in 
the future. It could even be part of a validation effort to describe the intrinsic metabolic 
capacity in the indicator cells. Only when co-culture systems or enzyme fractions would be 
used, the residual metabolism in the target cell type may become less important because it 
would be overwhelmed by the added metabolic capacity. If the residual metabolising 
capacity of indicator cell lines would be sufficient to produce active metabolites of inactive 
parent compounds and to deactivate EDs, this might constitute an unexpected but useful 
model to study metabolism and an ED mechanism simultaneously. If such models would 
indeed exist, a next step to further improve them may be to enhance the metabolic activity, 
to make it more reproducible and predictable and finally to make the level of metabolic 
activity a better simulation of the in vivo situation by using genetic engineering techniques. 
This possibility is another reason why residual metabolism in all cell lines that will be used 
in validation studies for ED testing should be determined. 
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The advantage of exogenous metabolising systems is that the enzymes are in direct contact 
with the xenobiotics without the need to first penetrate into the cell. However, unless the 
toxicity system is subcellular (e.g. a receptor binding assay) or the target is located in the cell 
membrane (e.g. membrane receptor), the resulting metabolites have to enter the cells to exert 
their effect. As a major  target for EDs are NRs, penetration of the formed metabolite and/or 
the parent compound into the cell will be required in most cases. In the case of co-culture 
systems, the xenobiotics have to enter the metabolically-competent cells, then leave them 
and enter the indicator cells or interact with targets located in their membranes. In cells 
genetically-engineered to metabolise and detect toxicity, the metabolites are generated in 
close proximity to the target site(s) for toxicity if they are located intracellularly but they 
need to exit the cells again if they are acting upon membrane bound molecular targets. As 
receptors for hormones such as estradiol may be located intracellularly or on the membrane, 
the location of the target and site of metabolite formation may be important issues to 
consider with regard to models intended for study of the metabolism and effects of EDs. The 
transport through the cell may need particular attention if transport proteins are present in the 
in vitro system utilised. 
 
There are many different cell lines that have been genetically-engineered to express various 
phase I and phase II enzymes and also a combination of both for use in toxicity testing 
(Doehmer, 1993; Macé et al., 1998). In a review by Friedberg et al. (1999), a comparison 
was made of insect, bacterial, yeast, and mammalian metabolism models. In general, the 
catalytic properties of CYPs in the various models were rather similar. 
 
A recent and promising innovation is the use of established cell lines, such as V79 cells, 
which have been genetically engineered to express selected genetic variants of human CYP 
enzymes, so that polymorphic effects can be assessed (Coecke et al., 2001). Very recently, a 
V79 cell line has be generated that expresses mouse CYP 2E1 to permit interspecies 
comparisons (Bernauer et al., 2003b). These cell lines, in common with several others, have 
a number of benefits including a stable diploid karyotype, no CYP background activity, and 
they can be transfected with rodent and human CYPs. This allows an investigation of the   33 
contribution of specific isozymes to metabolism and also studies on species specificity. 
However at a recent ECVAM workshop on in vitro models to study metabolism, there was 
consensus that at least at present, only limited numbers of P450 can be expressed in the same 
cells without affecting their viability (Coecke et al 2006). 
 
A further consideration when choosing a metabolising system is the well-known problem of 
preferential activation in vitro.  This is due to the fact that the use of enzyme homogenates 
under normal conditions favours Phase I metabolism, rather than conjugation reactions.  This 
can be overcome to some extent by adding cofactors for phase II reactions, but this is usually 
taken better into account when using whole cells such as hepatocytes, and others that express 
both phase I and II reactions.  At the recent ECVAM workshop, the use of human 
hepatocytes was not considered to be possible at present for screening on a large scale. 
 
2.3  The relevance of metabolism to the testing of endocrine disruptors 
One of the most frequently cited limitations of in vitro assays concerns the qualitative and 
quantitative deficiencies in the metabolism of test chemicals, in comparison with in vivo 
metabolism. This is a particularly important consideration when testing EDs since several, 
hormonally-active chemicals, including some naturally-occurring EDs, are known to be 
subject to metabolism (Table 3). False positive data could be generated due to the lack of 
metabolic detoxification of test chemicals, and false negative data could arise, if the required 
metabolic processes for activation are lacking in the in vitro system used. 
 
Most information on metabolism of hormonally active substances has been derived 
principally from studies with endogenous steroids, but of course it applies in principle 
equally to exogenous steroids with potential ED activity, and to any chemical that can 
modulate the homeostasis of the endocrine system (Honkakoski and Negishi, 2000). In 
addition, the effects of certain EDs are due to interference with the metabolism of the 
endogenous hormone and hence with its biologically available concentration. In other words, 
the use of test systems capable of metabolism should be an integral part of ED testing. The 
need to model metabolism is an argument that has been used in part to justify the need for   34 
animal-based tests for EDs, but it is an equally important reason to incorporate metabolic 
capacity in in vitro assays. 
 
Methoxychlor (bis[p-methoxydichlorophenyl]trichloroethane - MC) has estrogenic activity 
in vivo in a mouse uterotrophic assay, while it is inactive or virtually inactive in vitro in 
mouse uterine ER binding and HeLa ER cell transcriptional activation assays (Shelby et al. 
1996). Substances like the di-hydroxylated metabolite of methoxychlor, 2,2-bis(p-
hydroxyphenyl)-1,1,1-trichloroethane (HPTE), are estrogenic and anti-androgenic in vitro 
and their formation in vivo can explain the estrogenicity and antiandrogenicity of 
methoxychlor (Gaido et al. 1999). Methoxychlor is an interesting example of an ED that is 
metabolised because it illustrates many of the aspects related to metabolism that are 
important for the action of endocrine disrupters and that need to be taken into account when 
developing tests that will measure metabolism and endocrine effects in vitro. This chemical 
undergoes sequential de-methylation by CYPs 2C19 and 1A2 yielding mono-demethylated 
and bis-demethylated metabolites. These metabolites are hydroxylated at the ortho position 
on the ring to yield phenolic groups by CYPs 3A4 and 2B (Stresser and Kupfer, 1998a 
1998b; Dehal and Kupfer, 1999). CYP2C19 converts methoxychlor into a phenolic 
monodemethylated derivative that can be further hydroxylated in the ortho position by 
CYP3A4 while CYP3A4 does not cause O-demethylation or hydroxylation of methoxychlor 
(Stresser and Kupfer, 1998b). This observation means that a prosubstrate is turned into a 
substrate by one CYP for another CYP (Stresser and Kupfer, 1998b). In other words caution 
is needed before concluding that a particular P450 is not involved in the metabolism of a 
compound based on the use of an individual cDNA-expressed enzyme (Stresser and Kupfer, 
1998b). CYPs known at present to be involved in the metabolism of methoxychlor are 
CYP1A2, 2A6, 2C8, 2C9, 2C19 and 2D6 for O-demethylation, CYP3A4, 3A5 and (rat) 2B1 
for ortho-hydroxylation, CYP 2B6 for O-demethylation and ortho-hydroxylation (Hu and 
Kupfer, 2000a; 2000b). CYP2B6 has, however, a very narrow substrate specificity (Hu and 
Kupfer, 2000b). 
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The bis-O-dimethylated metabolite of methoxychlor HPTE has estrogenic activity and is 
more potent and has higher efficacy than the parent compound (Bulger et al. 1978; Beresford 
et al., 2000; Shelby et al., 1996). HPTE also inhibited seminiferous cord formation in vitro 
much more than the parent compound methoxychlor (Cupp and Skinner 2001), probably 
again demonstrating its more pronounced estrogenic effect. HPTE also depresses 
gonadotropin-releasing hormone expression in a murine neuronal cell line probably because 
it is an estrogenic agonist (Roy et al., 1999). In another study, it was demonstrated that bis-
OH-methoxychlor is a more potent estrogen agonist than mono-OH-methoxychlor that in 
turn is more potent than methoxychlor (Kupfer and Bulger 1987). Moreover methoxychlor 
can also be converted into the metabolite 1,1-dichloro-2,2-bis(4-methoxyphenyl)ethene 
which is also a proestrogen. The bis- and mono-hydroxylated metabolites of this product are 
also estrogens (Kupfer and Bulger 1987). These authors have used rat liver microsomes and 
NADPH as the metabolising system in the presence of immature rat uteri ER as the bioassay. 
If this test system could be standardized, validated and preferably make use of human 
microsomes, it may be one way of incorporating metabolism by human enzymes into in vitro 
testing for endocrine disruption. 
 
HPTE has anti-androgenic effects because it is a receptor antagonist (Maness et al. 1998). In 
addition, HPTE also decreased the production of testosterone by rat Leydig cells because it 
reduced steady-state messenger ribonucleic acid levels of the CYP cholesterol side-chain 
cleavage enzyme (Akingbemi et al., 2000). This means that the compound may have anti-
androgenic effects by decreasing the amounts of natural agonist that are available. In 
addition, methoxychlor and its bis and tris hydroxylated metabolites inhibited several other 
CYPs (Li et al. 1993). 
 
The estrogenic potency of methoxychlor in the yeast cell assay was markedly increased after 
incubation with human hepatic microsomes because of the conversion to metabolites 
including HPTE (Elsby et al., 2001a). Although the yeast cell assay is frequently used and it 
might be a good candidate to be used in conjunction with human microsomes if sufficiently 
standardized and validated, as previously noted there can be potential shortcomings that   36 
have led to some objections against its use (ICCVAM 2003). In another in vitro system 
employing a recombinant yeast cell bioassay expressing the human ERα linked to a reporter 
gene, the estrogenic effect of the potential methoxychlor metabolite 
bishydroxymethoxychlor was larger than that of the parent compound (Coldham et al., 
2002). The activity of potential metabolites of mestranol and isoxanthohumol (17α -ethynyl 
estradiol and 8-prenylnaringenin respectively) at the ERα was also larger than that of their 
parent compounds (Coldham et al. 2002). Incubation of mestranol or methoxychlor with rat 
liver microsomes that were activated with Aroclor 1254 (S9 fraction), increased the potency 
of these compounds in the bioassay. Metabolites that were identified and possibly 
responsible for the increased activity, included 17α -ethynyl estradiol for mestranol and 
monohydroxy- and bishydroxy-methoxychlor for methoxychlor (Coldham et al. 2002). There 
was no evidence for metabolism of isoxanthohumol in this combined assay (Coldham et al. 
2002). Mestranol was also activated by microsomes that were induced with saline (control), 
β -naphthoflavone, 3-methylcholanthrene, isoniazid, pregnenolone-16α -carbonitrile but not 
phenobarbitone (Coldham et al., 2002). 
 
It should be noted that HPTE is a preferential ERα  agonist with antagonist activity on ERβ  
and the AR in human hepatoma cells (Gaido et al., 1999; 2000) and that the gene expression 
that is caused by HPTE in mice is similar but not the same as that caused by estradiol 
(Waters et al., 2001). The pattern of activity on ERα , ERβ  and ARs in human hepatoma 
cells may be different among close analogs of methoxychlor (Gaido et al. 2000). These 
findings further illustrate that functional assays are needed when including metabolic 
capacity into ED screening and they also illustrate that it may be necessary to study different 
subtypes of ERs. 
 
As an androgen antagonist, HPTE is about 10 times more potent than methoxychlor in a 
HepG2 human hepatoma cell line transiently transfected with the human AR and an 
androgen-responsive reporter (Maness et al, 1998). This suggests that under these particular 
assay conditions, the cells did not have the metabolic capacity to convert methoxychlor into 
its metabolite. This raises the question whether hepatocytes with metabolic competency and   37 
containing the SHRs mentioned can be constructed to produce a more useful screening 
assay. 
 
The bis- and trishydroxymethoxychlor and a catechol methoxychlor metabolites can be 
formed from methoxychlor in vitro, by incubation with supersomes that have human cDNA 
expressed CYPs or when incubated with human liver microsomes (Hu and Kupfer, 2002a). 
The metabolism of methoxychlor by various CYPs, under these circumstances, is even 
subject to specificity towards the enantiomers (Hu and Kupfer, 2002b). 
 
Another study showed that Aroclor-1254 induced rat liver S9 fractions are compatible with 
MCF-7 estrogenic assays and that the activity of methoxychlor was increased while that of 
estradiol was decreased by co-incubation of the assay cells with S9 (Charles et al. 2000). 
This illustrates that the combination of S9 systems with MCF-7 cells is technically possible 
and the system is able to detect estrogenic activity of compounds that need to be converted 
to an active metabolite. 
 
Methoxychlor metabolites interact with  the CAR and induce CYP2B via a mechanism 
unrelated to estrogenic activity (Blizard et al., 2001). It is known that induction of enzymes 
including many CYPs and phase II metabolism enzymes can occur through NRs and in 
particular the CAR, the PXR (Lehmann et al 1998;Handschin and Meyer 2003) but also the 
glucocorticoid receptor and the peroxisome proliferator-activated receptor α  (Hines et al. 
2001, reviewed in Jacobs 2005). CAR and PXR are responsible for the induction of various 
CYPs (CYP2B and  CYP3A respectively ) and drug transporters in human cells, but they do 
not influence the basal expression levels (Friedman et al. 2002). Phenobarbital and (1,4-
bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) are known agonists of CAR, whereas 
lipopolysaccharide is an inhibitor (Wei et al. 2000, Tzameli et al. 2000). PXR activation 
leads to induction of CYP3A, but also to a lesser extent CYP2B and there are extensive 
species differences in xenobiotic PXR activation. Dexamethasone and rifampicin are known 
agonists of human PXR (Moore et al 2000a; Friedman et al. 2002;  Frank et al. 2005;) as are 
some phytochemicals and their metabolites, organochlorine pesticides and  bacteriocides   38 
(Moore et al 2000b; Jacobs et al 2004). The anticancer drug ET-743 is an inhibitor of PXR 
(Sparfel et al. 2003, Friedman et al. 2002). The effect of a potential ED can be investigated 
in several hepatic and kidney  cell lines the Hep G2 cell line by measuring the CAR and 
PXR levels in the absence or presence of the substance and also in combination with a 
known agonist of CAR or PXR respectively (Goodwin et al. 2002, Friedman et al. 2002). 
Furthermore, CYP2B6 and CYP3A4 mRNA levels can also be used to investigate the effect 
on CAR and PXR (Friedman et al. 2002). The cells should be incubated with an ED alone or 
in the presence with a known inducer of CAR or PXR. If the ED leads to in induction of 
CYP mRNA, the effect on the receptor should be verified with a known inhibitor of CAR or 
PXR. The mRNA levels can be measured with real-time reverse transcriptase-polymerase 
chain reaction (RT-PCR) with specific primers for CYP2B6, CYP3A4, CAR and PXR and a 
reference gene with stable expression in the cell (e.g. GAPDH). Whether a ligand-binding 
assay for these receptors or the measurement of mRNA for the enzymes involved in 
metabolism, might be a valuable tool to predict induction of metabolism by a number of 
chemicals might depend upon the number of positives in such tests, the ultimate value for 
the prediction of their in vivo effects and the additional costing. 
Western blotting and PCR may provide a very good methodological tool to measure mRNA 
levels of certain CYP enzymes in order to evaluate the effects of a certain chemical on a 
certain receptor. Nevertheless, measurement of mRNA does not necessarily reflect the 
induction of xenobiotic metabolising CYP enzymes at the protein or activity level (Sumida 
et al., 1999; Tew et al., 1996). Therefore, the induction of certain xenobiotic-metabolising 
CYP enzymes could also be investigated in the following way (in the case of CYP2E1, this 
has been applied in Bernauer et al. 2003a, b): cells can be incubated with an inducer and 
with the probe substrate of the CYP enzyme to be investigated. After incubation, the 
metabolites (specifically formed under the influence of a certain CYP enzyme) can be 
quantified by well established activity assays (given in Table 5). Alternatively, cell protein 
can be isolated after culture. Cell protein can be incubated with the CYP substrate and 
metabolites can be quantified. In addition, Western Blotting analysis of the relevant CYP 
enzyme can be performed in the cell protein by using commercially available antibodies. 
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In rats exposed to methoxychlor for 4 days, a decreased conversion of thyroxine to 
triiodothyronine was observed, probably because one or more metabolites bind to 5’-
monodeiodinase type 1 (Zhou et al., 1995; Morrell et al., 2000). It is not immediately clear 
whether this is an important effect for the endocrine actions of methoxychlor, nor whether it 
would occur with other compounds. This finding may reinforce the idea that considering 
testing for thyroxine metabolism and thyroid receptor activation may indeed be worthwhile 
at some stage of ED screening. 
 
Methoxychlor and its metabolites, including mono- bis- and tri-hydroxylated compounds, 
may bind covalently to hepatic microsomal proteins, and this is catalysed by CYPs (Bulger 
and Kupfer, 1990), but demethylation is not an essential prerequisite. This finding is an 
illustration of the potential importance of protein binding in in vitro assays. 
 
In catfish, methoxychlor alone or in combination with β -naphthoflavone alters the capacity 
of liver microsomes to metabolise methoxychlor in vitro (Schenk et al. 1997). Pretreatment 
with the CYP1A-inducer β -naphthoflavone did not affect the metabolite pattern of 
methoxychlor alone, but when administered simultaneously, a reduced metabolism of 
methoxychlor was observed and yet estrogenicity was increased (Schenk et al. 1997). 
While it is not clear in this paper which factor(s) caused the increased estrogenicity,   the 
involvement of cross-talk between additional receptor and non-receptor mediated 
pathways, particularly with respect to the recently elucidated relationship between AhR and 
ER (Ohatake et al 2003), also PXR, and suppression of SULT enzymes (thereby increasing 
the pool of free estrogen) for example could be part of the explanation (reviewed in Jacobs 
2005).  An additional part of the explanation may also be species differences in the 
sensitivity for certain metabolites. 
 
The example of methoxychlor indicates that metabolism can influence the endocrine 
disrupting properties of a chemical in different ways by forming metabolites with increased 
potency and efficacy, by forming metabolites that act on different molecular targets, or that 
have an increased potency at one receptor and that become antagonists at different receptors.   40 
One should thus consider testing of metabolites for different endpoints, as part of a tiered 
testing strategy, to tease out the mechanistic basis underlying the key steps in interrelated 
metabolic pathways. It seems most useful to include one particular molecular target or effect 
in each test to obtain reproducible results that can be easily interpreted. On the other hand, 
the potential effects of metabolites on different targets and the possibility of one metabolite 
being an agonist on one system and an antagonist on another system may make the 
extrapolation of individual test results to the intact organism difficult but not impossible. If 
one considers metabolism of chemicals, the effect of different enzymes in cascade may be 
quite different from the sum of effects of individual enzymes, and metabolism may even not 
take place when using only one enzyme. It may thus be more realistic to have as many 
enzymes available as possible in one particular test in amounts relevant to the in vivo 
situation. This implies that several metabolising enzymes would need to be incorporated into 
cells if one uses genetically engineered cells for testing. One question to be answered is 
whether particular metabolites that may be more potent than the parent compound are 
formed in sufficient amounts to significantly contribute to the ultimate effect. Obviously the 
amount of the different enzymes expressed, and their activity in the test should therefore be 
representative for the situation in the intact organism. This may not be easy to achieve with 
genetically engineered cells designed to express the enzymes involved. A workshop that was 
recently organized by ECVAM also revealed that it is even not yet possible at this moment 
to express many different CYPs in the same cells and keep them in culture. For these 
reasons, the use of genetically engineered cells may be possible in the near future, and in the 
long run may represent the ideal test method. Maybe, as a first approximation, parallel or 
sequential use of different cell lines expressing different xenobiotic metabolising P450 
enzymes might be discussed. On the other hand fully competent metabolising cells like 
hepatocytes are not yet useful for validation screening purposes (with respect to 
reproducibility) on a large scale, and in particular if human hepatocytes are required (see 
Blaauboer B. et al. 1994). Availability and variability (different age, gender, condition and 
also loss of P450 expression/activity) will constitute a problem and it is not evident to grow 
hepatocytes in culture under stable conditions to allow screening of large series of 
chemicals. Furthermore, the reproducible expression of the molecular target that would   41 
constitute the endpoint to be measured in the hepatocytes or viable co-cultures with the 
indicator cells would be required. 
 
The finding that metabolism by certain cytochromes may be specific for some enantiomers 
and the likelihood that at least for a number of chemicals the interaction with the target 
receptor may also be specific for certain enantiomers may indicate that particular attention 
will need to be paid to the testing of chemicals with chiral centers. 
 
Furthermore the interference by methoxychlor or its metabolites with the turnover of thyroid 
hormones suggests that the metabolism of other hormones than estrogens may need more 
consideration than it has received in the past. 
 
Perhaps the most important findings with methoxychlor are that it seems possible to 
combine the use of S9 fractions or microsomes with in vitro assays that measure estrogen 
function, allowing detection of agonist and antagonist effects, in indicator cells that contain 
human ERα . Detection of activity from the metabolites that are formed is possible. The 
assays involved are the MCF-7 and the yeast cell assay that are often used and relatively well 
known. The latter test may be equally suited for incorporation of other hormone receptors, 
which would broaden the scope of its usefulness. The assay that was mentioned earlier as the 
ER CALUX (Legler et al. 2002a, b) also uses a combination of S9 and measurement of 
estrogenic activity. Provided that the test can be made sufficiently specific it may offer an 
alternative testing method (Rogers and Denison 2000). 
 
Another example of the importance of metabolism in the determination of endocrine effects 
is the conversion of tamoxifen to its 4-OH derivative. This conversion is required to confer 
increased anti-estrogenic activity on the molecule (Cassidy and Milligan 1998) and is 
catalysed by CYPs 3A4 and 2D6 (Dehal and Kupfer 1998, 1999). The mandatory conversion 
of chlorobiphenyl to 2-chloro-4-hydroxy-biphenyl to become estrogenic (Rosenkranz, 
unpublished) further illustrates the need for incorporation of metabolic capacity in in vitro 
tests. Aryl methyl sulfone metabolites of polychlorinated biphenyls (PCBs) and of 2,2- bis(4-  42 
chlorophenyl)-1,1-dichloroethene, on the other hand, can behave as estrogen antagonists 
(Letcher et al. 2002). Methyl sulfonyl PCBs also interact with glucocorticoid receptors 
(Johansson et al. 1998). 
Dexamethasone is an example of a synthetic steroid with therapeutic activity, which is 
hydroxylated in a regio-selective way (Lewis, 1996; Amrani et al., 1999). 
Polybrominated  diphenyl ethers (PBDEs) and some of their metabolites exert in vitro 
estrogenic effects in three different cell line assays based on ER-dependent luciferase 
reporter gene expression (Meerts et al. 2001), but these findings have not been confirmed. 
The purity of PBDE (as with every substance) should be carefully assessed before use in an 
assay.  
Vinclozolin forms two metabolites: 2-[[3,5-dichlorophenyl-carbamoyl]oxy]-2-methyl-3 
butenoic acid, also termed M1, and 3’,5’-dichloro-2-hydroxy-2-methylbut-3-enanilide, also 
termed M2 (Wong et al. 1995). While both are AR antagonists, M2 is a more potent ligand 
than the parent molecule and M1 has a slightly weaker binding affinity than vinclozolin in 
the same test (Wong et al. 1995). Although metabolism may therefore not be an essential 
prerequisite for the ED activity of vinclozolin, the metabolites contribute and depending on 
the predominant metabolite formed, there may even be an enhancement of the activity, in 
comparison to that of the parent compound. 
 
The reports above show that a number of metabolites of substances are more potent than or 
at least as potent as EDs in comparison to the parent compound, and there are many more 
examples in the scientific literature, particularly for persistent organic pollutants including 
bacteriocides and pesticides. Also metabolism can convert agonists into antagonists. This 
suggests that inclusion of metabolism is needed in ED testing to increase the sensitivity of 
the test and to augment the reliability to predict the effect of a chemical. It could be argued 
that the tests which are presently available, would detect the parent compounds because of 
their relatively high sensitivity. However, because there is no information available on the 
metabolites of the majority of chemicals, it is not known how many are currently not being 
detected as EDs because the parent compound is not sufficiently potent. In the long term it 
might also become an advantage for accurate hazard and risk assessment if one could predict   43 
the potency of the actually formed ED metabolites rather than the less potent parent 
compound. Furthermore, it may be of added value in terms of risk assessment to know that 
active metabolites could be formed, because these may prolong the action of a xenobiotic if 
the parent compound is not persistent and has a short half-life. 
 
2.4  Potential problems with using exogenous metabolism in studies of 
endocrine disruptors 
The paucity of published studies involving the use of exogenous metabolism in in vitro 
assays for EDs is surprising. It is recognised that there could be difficulties when adding 
exogenous metabolising fractions, e.g. due to non-specific hormone binding to protein in the 
enzyme fractions or to cytotoxicity of these fractions to target cells. Several EDs are known 
to bind strongly to serum proteins, and when this phenomenon occurs in vivo, it will affect 
internal target tissue concentrations of the chemical involved (Safe et al., 1997). Such 
binding can occur with components of culture media or metabolising systems like S9, 
thereby resulting in both variable in vitro data, and differences in responses obtained in in 
vivo and in vitro assays. This phenomenon could be alleviated by removing proteins that are 
not necessary for testing from the medium. It is clear that protein binding of potential EDs 
will need to be carefully studied in the first place because it might be an important 
determinant of its in vivo activity, but also to better interpret results from in vitro studies. 
A study on 64 chemicals performed in a reporter gene assay making use of S9 indicated that 
there are two potential problems associated to the use of S9. Trans-stilbene was used as a 
reference agonist because it needs to be hydroxylated to trans-4-hydroxystilbene and trans-
4,4’-dihydroxystilbene in order to be active. With the amounts of S9 required, estradiol at 
normally active concentrations was inactivated, while higher concentrations of estradiol 
where again more active with S9, than without. This is explained by an inversion of the 
concentration response curve that has a maximum at about 100 pM. The second problem that 
was encountered was the low reproducibility (Personal communication: Masahiro 
Takeyoshi, Gene analysis section, Hita laboratory, Chemicals Evaluation and Research 
Institute, Japan). 
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The logistical problems described above in using exogenous metabolism and developing 
new cell strains capable of acting as indicators of ED activity and of metabolising such 
chemicals in a relevant way have prompted a relatively recently published report (ICCVAM, 
2003) on the use of in vitro binding and transcriptional activation (TA) assays for EDs, to 
conclude that 'the inclusion of a metabolic activation system in in vitro ER and AR binding 
and TA assays is not recommended at this time, as the type of metabolic activation system 
developed will depend on which in vitro assays are selected.' 
 
There is one other potential complication relating to what is known about the structural 
requirements for estrogenicity, in particular binding to the ER. As stated earlier, many 
estrogens contain one or more phenolic groups on a relatively small lipophilic molecule. 
C-hydroxylation on ring structures is precisely what occurs as a result of initial CYP 
monooxygenase activity on xenobiotics and this may result in many substances that will be 
detected as estrogenics in vitro. In vivo, a number of these will be further metabolised and no 
longer be active. As a consequence, the use of metabolising systems that express 
predominantly phase I pathways, as opposed to phase II conjugation reactions, might be very 
prone to generating false positive data. This potential problem would need to be addressed.  
 
2.5.   Fetal metabolism and infant metabolism 
It is important to realize that phase I oxidative enzymes may be expressed to a different 
extent during fetal life and also phase II enzymes are expressed differently in fetal life and 
during later stages (Hines and McCarver 2002; McCarver and Hines 2002) 
 
Thus not only may the metabolism of xenobiotics be different in the developing fetus, but 
also the synthesis and degradation of steroids may be differ. As the fetus may be particularly 
sensitive to the effect of EDs  (see for example McLachlan 2001 and the European Union’s 
Environment and Health Strategy: SCALE, 2003 and Action Plan, 2004), future work to 
investigate the possible interactions of EDs with the CYP family in the fetus may be needed. 
There is experimental evidence for the presence of CYP1A1, CYP2C8, CYP2D6, CYP2E1,   45 
CYP3A4, CYP3A5, CYP 4A1 and particularly CYP1B1 and CYP3A7 in the fetal liver (de 
Wildt et al. 1999; Hakkola et al. 1998). 
Many CYPs are absent or barely detectable in the foetal liver, and develop postnatally. Three 
major stages in the expression of P450 enzymes can be discerned: CYP3A7 and 4A1 are the 
predominant CYPs expressed in the foetal liver and, a second group of early neonatal 
enzymes include CYP2D6 and 2E1 which surge within hours after birth although these 
proteins have not been detected in fetal samples. CYP3A4 and CYP2Cs rise during the first 
weeks after parturition, while CYP1A2 is the last isoform to be expressed in the human 
neonatal  liver. Among phase II enzymes, epoxide hydrolase and glutathione S-transferase π 
are very active in the fetal liver, whereas glutathione S-transferases and UDP glucuronosyl 
transferases develop within 3 months after birth (Cresteil 1998). 
 
2.6.   Metabolism during digestion 
 
The diet represents a major route of exposure to possible EDs and the chemical 
transformations which can occur during digestion further complicate considerations of 
metabolism. The myriad of processes involved in digestion have proven difficult to model, 
but two particular studies have emphasized the importance of examining these sorts of 
transformations in in vitro assays.  First, nitrosylation reactions can occur in the saliva and 
acidic pH of the stomach through reaction of amines, phenols and mercaptans with sodium 
nitrite, a common food preservative and product of gut microbe-mediated reduction of 
nitrate (Assembly of Life Sciences., 1981, Chapters 4 and 6; Spiegelhalder et al. 1976; 
Tannenbaum et al. 1975; Challis 1973).  The phenolic structure of several EDs makes them 
susceptible to nitrosylation, and although the reaction has attracted more attention as a 
mechanism of mutagenic activation, hormonal activity may also be modified.  Nitrosylation 
of Bisphenol A, an estrogenic component of plastics and epoxy resins, causes both 
mutagenic activation and a decrease in estrogenicity as measured by green fluorescent 
protein reporter gene activity and ERα binding assays (Schrader et al. 2002; Masuda et al. 
2005).  A second effect of digestion on hormonal activity is evident in comparisons between 
the soy isoflavone daidzein and its metabolite equol.  Equol is produced by intestinal   46 
hydrolysis of the glycoside followed by bacterial biotransformation (Setchell et al. 1984, 
2002) and has been shown through cell proliferation and receptor binding studies to be a 
much more potent ligand than the parent compound for ERα (Lehman et al. 2005; Setchell et 
al. 2005) and PXR (Jacobs et al. 2005), although it is metabolised far more rapidly than 
synthetic EDs, which are often more persistent. 
 
3.  THE METABOLISM OF ENDOGENOUS STEROIDS 
3.1 Introduction 
The steroid ring structure is a substrate for phase I metabolism by numerous CYP isozymes 
with multiple hydroxylations (Table 4) occurring at a number of preferential sites around the 
steroid molecule. Several of these reactions are concerned with the biosynthesis of different 
endogenous steroids from cholesterol via the formation of pregnenolone (See Fig. 2; Jacobs, 
2004 and Fig. 3: Mensah-Nyagan et al. 1999). The initial biosynthetic reaction involves 
CYP-catalysed cleavage of the 6-C group from cholesterol, to form C-18, C-19 and C-21 
steroid ring structures. Further reactions are catalysed by another isozyme (aromatase or 
CYP19), that converts the intermediate androgen structures in the biosynthetic pathway to 
estrogens via a process of aromatisation (thus the enzyme is known as aromatase). Other 
CYP isozymes are responsible for the activation or inactivation of the steroid substrate, as 
discussed below.   
 
The various CYP isozymes responsible for hydroxylation are usually designated according to 
the substituent position that is hydroxylated. Also the enzymes exhibit stereochemical 
selectivity, with both hydroxylations being possible at the same or at different sites, 
depending on whether the resulting substituent is orientated above or below the essentially 
planar ring system. There are also some sex- and age specific differences in steroid 
metabolism (Jacobs and Lewis 2002), and whether or not animal models  have been 
castrated or ovariectomised, can also affect such metabolism (Steimer, 2003).   
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A wide variety of CYP isozymes are able to hydroxylate steroids, although the most 
important groups of isozymes with respect to the quantity  and variety of hydroxylations 
involved are the 3A and 2C isozyme groups (Table 4). CYP3A4 is known to be able to 
hydroxylate estradiol (Stresser and Kupfer, 1997). This enzyme also plays a prominent role 
in human the metabolism of xenobiotic chemicals and drugs. It is obvious that if hormones 
and xenobiotics are the substrate of the same enzyme there is a potential for complicated 
interactions. The enzyme may generate active metabolites from an inactive precursor or it 
may form inactive metabolites from an ED. The mere fact that xenobiotics, while being 
metabolised, are competing with endogenous substrate may also result in reduced 
biotransformation of the latter, which may induce ED effects. The degree of competitivity or 
irreversibility of the interaction between a xenobiotic and the enzyme may be anticipated to 
be an important determinant of the effect. The interaction of xenobiotics with a number of 
key enzymes may be examined in vitro in a first attempt to determine its metabolic pattern 
and for this purpose genetically engineered cell lines which express CYPs can be used. 
 
Estradiol and testosterone are the two most widely studied endogenous steroids with regard 
to CYP metabolism. The former has been studied extensively due to its use as one of the 
active ingredients of the female contraceptive pill and its potential association with the 
aetiology of breast cancer (Lord et al., 2002). Estradiol is converted into numerous 
metabolites, the best known of which are estrone and oestriol. Estrone is further 
hydroxylated at the 2-, 4- or 16- positions by different CYPs (Table 4). Following estrone 
hydroxylation, further hydroxylations occur to form the respective poly-hydroxy derivatives 
that are then substrates for methylation or conjugation with glucuronic acid or sulfate.  In a 
study involving human recombinant CYPs, it was shown that CYPs 1A2 and 3A4 exhibited 
the highest activities toward estrone (Shou et al., 1997), while CYPs 3A5, 2C9 and 
2C9R144C exhibited only moderate activities. The 2-hydroxylated product was formed 
exclusively by CYP1A2 and an unknown hydroxylation product was formed by CYP3A4.   
 
Testosterone is hydroxylated by a wide variety of CYP isozymes at a variety of positions 
(Table 4). However, the major form of metabolism is 6β - hydroxylation catalysed by   48 
CYP3A isoforms (Lewis, 1996). The CYP2B isoforms generally exhibit regio-selectivity at 
the 16 and 17 positions of testosterone, with 2B1 exhibiting hydroxylase activity at the 16- 
α , 17-α  and 16β - positions. Testosterone is also hydroxylated at the 4 position by CYP2D6 
(Dehal and Kupfer, 1997). 
 
Interestingly, progesterone is not only subjected to 17-hydroxylation, but also has been 
shown to be metabolised to its 21-hydroxylated metabolite predominantly by CYP2C5 
(Kronbach et al., 1989). This enzyme exists as two isoforms in rabbits (Pendurthi et al. 
1990) and similarity to CYP2C9 is suggested but remains to be confirmed (Afzelius et al. 
2001, 2004). 
 
Thus, the CYP enzymes exhibit catalytic activity toward a number of endogenous steroids, 
and this activity can be influenced by a number of factors, especially age, sex and disease, 
which are likely to be important in maintaining homeostasis in hormone levels at different 
times of development. Other important modulating influences on hormone metabolism 
include lifestyle, smoking, alcohol, diet and drug use and abuse, and individual differences 
due to genetic polymorphisms (Hatagima, 2002). The genetic polymorphisms that are most 
relevant to the enzymes that play a role in the metabolism of xenobiotics have recently been 
reviewed (Wormhoudt et al. 1999; Pelkonen et al. 1999). 
 
 
Some chemicals that have estrogenic activity despite having low affinity for the ERs, such as 
hydroxylated PCBs and polyhalogenated aromatic hydrocarbons (PAHs), may exert this 
effect by inhibition of estrogen sulphotransferase, as discussed in section 2)  thereby 
maintaining the available estrogen at higher levels (Kester et al. 2000, 2002; Shevtsov et al. 
2003) as well as via the ER. Whereas Kester et al. used enzymatic assays, as with Warings 
group (Harris and Waring 2005) to investigate this possibility, Shevtsov et al. made a first 
attempt to study structural aspects using the crystal structure of the enzyme.  
Other Detailed Review Papers are dealing in much more detail with the enzymes involved in 
the synthesis of steroids and with aromatases. It is however important to realize that there is   49 
a link between the metabolism of xenobiotics and steroids through the many enzymes that 
participate in both pathways. In particular when developing tests to detect antagonistic 
effects of chemicals this is crucial since the natural hormone will be most likely used as the 
agonist and the incorporation of metabolic capacity is likely to have effects on the 
concentration of the agonist that should be taken into account while devising the test. 
 
3.2  Metabolic activation of endogenous steroids 
It is well-established that endogenous steroids can be converted to active metabolites and to 
inactive metabolites in target tissues (see Steimer, 2003 for a review). In the former case, as 
with many potentially toxic substances, some steroids have to be converted in situ to an 
active form before being able to interact with their respective receptors. This metabolic 
activation step is either an absolute pre-requisite, or a way of achieving a range of complex 
effects which give rise to interactions with more than one type of receptor. 
 
A well-known example is the conversion of testosterone to 5α -dihydroxytestosterone, a step 
that is necessary for its action on prostate growth, whereas its aromatisation to 17β -estradiol 
in the brain is required for its developmental, neuro-endocrine and behavioural effects. 
Metabolic activation has been shown to play an important role in the activities of several 
other steroid hormones, including the progestins and androgens. Enzymes involved in 
metabolic activation of steroids usually catalyse irreversible conversion steps, and are often 
rate-limiting for steroid action (i.e. the effects depend more on the efficiency of metabolism 
than on the number of receptor molecules (binding sites) available). 
 
Estradiol is converted by CYP enzymes to a number of biologically active metabolites, with 
some of them being estrogen antagonists. For example, while the 2- hydroxy metabolite of 
estrone is inactive, the 16α - hydroxy metabolite is antagonistic, as are the 4-hydroxy 
metabolites, although they are produced in lower amounts. 
 
There is much information implicating the formation of estrogenic metabolites of estradiol 
(such as 16α -hydroxyestrone) as being carcinogenic and associated with the development of   50 
breast cancer in humans (Lord et al., 2002).  The relative amounts of 2-hydroxyestrone and 
16α -hydroxyestrone can be measured in human urine by using an ELISA method, and the 
ratio of the latter to the former metabolite is elevated in patients with breast cancer, although 
the existence of this link is controversial (Safe, 2000). CYP1A1, which is inducible by active 
ingredients of cruciferous vegetables at high doses, is responsible for generating the 2-
hydroxy metabolite. Cruciferous vegetables are known to reduce the risk of breast cancer. 
The compounds involved include indole-3-carbinol, a weak ligand in the AhR and one 
which  may not ultimately induce CYP1A1 dependent enzymes. Observations reported in the 
literature suggest that the antiestrogenic effects of the active compounds in cruciferous 
vegetables may not ecessarily involve altered CYP dependent estrogen metabolism 
(reviewed in Kim & Milner 2005). In addition to receptor cross-talk (Ohtake et al., 2003, 
Jacobs 2005), other metabolic routes may include induction of  gluthathione-S-transferases, 
inhibition of other CYPs  as well as weak estrogen antagonist activity (Michnovicz et al. 
1997; Hecht 1999; Lampe et al. 2000; Meng et al. 2000; Rose et al. 2000; Chen et al. 2001; 
Nakajima et al. 2001; Sanderson et al. 2001; Ambrosone et al. 2003; Leibelt et al. 2003). 
 
Testosterone is also metabolised to androstenedione by 17β -hydroxysteroid dehydrogenase 
and by 3β -hydroxysteroid dehydrogenase.  A question that may need to be addressed is 
whether certain enzymes are specifically expressed in tissues like uterus, brain, testes, ovary 
and breast at a certain time in life and may be affected by some EDs with resulting changes 
in steroid levels and hence changes in hormonal balance at the local level, or on the other 
hand whether some of these chemicals might be metabolised by local CYPs with formation 
of locally active EDs. The breast is one of the tissues where local expression of CYP 
enzymes is described (Hellmold et al. 1995, 1998a,b; Stromstedt et al. 1993; Warner et al. 
1997, 1998), which may be relevant to endocrine disruption because of its sensitivity to 
estrogens. Gender considerations in P450 metabolism are clearly an important consideration 
(Lewis 2003). 
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3.3  Metabolic inactivation of endogenous steroids 
The metabolic inactivation of endogenous steroids occurs mainly in the liver, but also in the 
kidneys, and is required to ensure steady-state levels of plasma hormones, as steroids are 
more or less continuously secreted into the blood stream. There are five principal 
inactivation pathways, depending on the structure of the steroid substrate: a) reduction of the 
double bond at C4 and reduction of an oxo(keto) group at C3 to a secondary alcohol group; 
b) reduction of an oxo group at C20 to a secondary alcohol group; c) oxidation of a 17β -
hydroxy group; d) further hydroxylations at various positions of the steroid nucleus; and e) 
conjugation to form sulfate or glucuronide derivatives. 
 
Other extrahepatic tissues that may be important to consider are the skin and adipose tissue. 
The skin is particularly active in metabolising endogenous and exogenous steroids (the latter 
being applied topically as medicines for example) (Hotchkiss, 1992).  The cutaneous 
metabolism of steroids involves the co-factor-dependent hydroxysteroid dehydrogenases 
(Penning, 1997) which interconvert keto- and hydroxy- groups, and the 5α -reductases. The 
dehydrogenases catalyse the interconversion of testosterone and androstenedione, estradiol 
and estrone, as well as cortisone and hydrocortisone (cortisol). Also, the 7α - hydroxylation 
of dehydroepiandrosterone, and the hydroxylation of testosterone at the 7α -, 16α - and 6β - 
positions have been demonstrated, suggesting the activities of CYP 3A and 2C isozymes.   
RT-PCR analysis of proliferating keratinocytes from the human epidermis from 5 male 
donors revealed constitutive expression of CYP1A1, CYP1B1, CYP2E1, CYP2B6, and 
CYP3A5. Expression of CYP3A4 could be induced by dexamethasone (Baron et al. 2001). 
By using microsomes prepared from human keratinocytes, CYP1A1, CYP2B6, CYP2E1 and 
CYP3A could be determined by immunoblotting. These enzymes were also detected by 
immunofluorescence of differentiated keratinocyte multilayers and the respective enzyme 
activities could be detected in microsomes from human keratinocytes (Baron et al. 2001).  
Yengi et al. (2003) investigated 13 P450 enzymes by quantitation of P450 mRNA. In RNA 
isolated from human skin biopsies, CYP mRNA of the following enzymes could be 
quantified by RT-PCR in human skin samples from 27 healthy volunteers: CYP1B1, 
CYP2B6, CYP2D6, and CYP3A4. Lower levels were found for CYP2C18, CYP2C19, and   52 
CYP3A5, whereas CYP1A2, CYP2A6 and CYP2C8 were below limits of detection. Smith 
et al. (2003) investigated CYP2S1 expression in human skin biopsy samples. It could be 
demonstrated by RT-PCR of CYP2S1 mRNA, by immunohistochemistry and by metabolism 
of all trans-retinoic acid, that CYP2S1 is constitutively expressed in human skin. Cutaneous 
expression of CYP2S1 is inducible (for example by ultraviolet radiation or coal tar). It has 
been demonstrated, that CYP2S1 expression mainly occurs in epithelial cells (Saarikoski et 
al., 2005). Saeki et al. (2002) investigated mRNA from cultured Langerhans cells, 
keratinocytes, fibroblasts and melanocytes from 6 individuals. CYP1A1, CYP1B1 and 
CYP2E1 were found in all four cell types. CYP2A6, CYP2C, CYP2D6, CYP3A5, CYP3A7 
and CYP4B1 mRNA was expressed in a cell –type – and or individual specific manner. 
CYP1A2, 2A7, 2B6 and 3A4 mRNA was not detectable. In a recent review by Du et al. 
(2004) it has been summarized, that at least 13 different CYP2 genes (CYP2A6, CYP2A7, 
CYP2B6, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP2J2, CYP2R1, 
CYP2S1, CYP2U1, and CYP2W1) are expressed in skin from at least some individuals and 
that the majority of these genes is expressed in the epidermis or in cultured keratinocytes.  
3.4  The consequences of metabolism for hormonal activity 
It is well known that the affinity of steroids for their respective receptors is crucially 
dependent on the presence of specific functional groups, as well as on 3-D structure. Minor 
changes in these properties, for example as a result of metabolism, can drastically modulate 
binding affinity. Thus, it follows that target tissue metabolism can play a critical role in the 
activity of steroids. 
 
4.  THE TESTING OF ENDOCRINE DISRUPTORS AND 
METABOLISM 
4.1 Introduction 
Some substances like methoxychlor are relatively well studied with regard to metabolism 
and the hormonal activity of its metabolites (see section 2.3). Obviously the substances with 
hormonal activity that are used in medicine are also usually well documented. However  
substances with ED effects that are present in the environment are often less well studied.   53 
There are a few studies available with some other substances than those mentioned in 
section 2.3. 
 
A human microsomal metabolising system was used by Vakharia & Gierthy (1999) to 
generate hydroxy metabolites of some PCBs. The estrogenicities of the resulting metabolites 
of some of these parent compounds were determined by their abilities to bind to the ER. In 
some cases there was evidence for metabolic activation.  In a later study, it was shown that it 
is possible to incorporate a post-mitochondrial supernatant fraction (S9) into an assay 
involving a yeast hybrid system (Joyeux et al., 1997). There was evidence for the activation 
of some of the chemicals (13 bisphenol A-related chemicals) by S9 (Hashimoto et al. 2001). 
Yoshihara et al (2001) used a yeast hybrid assay and a mammalian cell system (the MCF-7 
cell line) to demonstrate that rat-liver S9 was able to enhance the estrogenicities of bisphenol 
A, bisphenol B and also methoxychlor. On the other hand 4-tert-octylphenol, 4-nonylphenol 
and 17β -estradiol were inactivated when metabolising capacity was added. These authors 
showed that the activating effects of S9 were due to CYP activity as they were abolished by 
SKF-525-A. They also they found that neither cytosol nor microsomes alone were able to 
activate the chemicals. In a later study they indicated that also human, monkey and mouse S9 
could form metabolites that are more active than the parent bisphenol and in particular 4-
methyl-2,4-bis(p-hydroxyphenyl)pent-1-ene should be mentioned (Yoshihara et al. 2004). 
This work needs to be confirmed and extended, and the issue of protein binding examined 
directly. Also, different types of enzyme fraction need to be used with sub-cellular receptor 
binding assays, as well as the use of different mammalian indicator cell lines. 
 
The same group (Kitamura et al., 2003) have more recently extended their studies to a group 
of styrene oligomers by using the same biological systems in the presence of rat liver 
microsomes. They showed that trans-1,2-diphenylcyclobutane (TCB), 1,3-diphenylpropane 
and 2,4-diphenyl-1-butene were only activated when microsomes from phenobarbitone-
induced rats were used, and when incubations were conducted in the presence of NADPH. 
The active metabolite of TCB was identified by HPLC as its 4-hydroxy derivative. Thus, 
these results differ from the former ones obtained by these authors in that microsomal   54 
fractions were able to activate the chemicals. Unfortunately, they did not specify whether an 
inducer had been used in the earlier experiments. Meerman et al (2003) have also shown that 
rat liver microsomes can be used to activate several polycyclic aromatic hydrocarbons to 
metabolites that can bind to the ER in binding, cell proliferation and reporter gene assays. 
More recently this group have also shown that dibrominated biphenyls are bioactivated by 
CYPs to metabolites with estrogenic activity and inhibiting estrogen sulphotransferase 
(hEST) (van Lipzig et al.2005). 
Using rat hepatocytes, bisphenol A glucuronide could be detected as a major metabolite 
(Elsby et al. 2001b). Glucuronidation by microsomes prepared from human livers was 
considerably less than that by immature female rat microsomes (Elsby et al. 2001b). 
Estrogenic activity of bisphenol A was determined in a yeast assay coupled with microsomal 
metabolism and estrogenicity was decreased less by the human microsomes than by the 
immature rat microsomes (Elsby et al. 2001b). This indicates that species differences need to 
be addressed and the physiological relevance of using rat or human systems should be 
established. In addition it was shown that in humans, bisphenol A may be rapidly excreted as 
glucuronidated metabolites (Völkel et al. 2002, 2005). 
 
Although some tests to measure endocrine effects and in particular estrogenic potency do 
already include assays for metabolism, these have not been (pre) validated and thus can be  
considered as being preliminary for regulatory purposes. They suggest however that tests 
designed to investigate both metabolism and an endocrine target simultaneously, are both 
possible and important for human hazard assessment. 
 
4.2  Possible ways to overcome problems of using exogenous metabolising 
systems 
The presence of serum proteins that may not only bind steroids, but possibly also exogenous 
EDs, may hamper the use of metabolising cell free systems or cells with metabolising 
capacity in conjunction with indicator cells that contain the endocrine target. This issue 
should be addressed carefully during the standardization and validation procedure. It may 
after all be advisable to incorporate a mandatory in vitro test to measure plasma protein   55 
binding of chemicals in future toxicological testing schemes. If protein binding does turn out 
to be problematical, then a potential solution would be to rely on the metabolism of the 
indicator cells. As discussed earlier, there are two ways of achieving this, either: a) to hope 
that the cells that are used in the assays have sufficient inherent and relevant enzyme 
activity; or b) to generate metabolically competent cell lines via the introduction of the genes 
for enzymes into the cells and by using culture conditions in which the enzymes are 
expressed. In both cases, intracellular metabolites can be generated in situ close to or at the 
sites of the relevant receptors. 
 
4.2.1  The intrinsic metabolising capacity of cell lines used for testing endocrine disruptors 
There is little known about the intrinsic metabolic competence of the usual mammalian cell 
lines that are used for detecting EDs acting via receptor binding, and such an investigation 
needs to be undertaken. In this context, it is of interest that discrepancies in the estrogenicity 
of methoxychlor (discussed above) in various in vitro assays have been attributed to 
differences in the metabolic competencies of the various indicator cells involved (Andersen 
et al. 1999). Thus it was assumed that some of the cells involved possessed some residual 
demethylating activity.  Also, evidently MCF-7 cells are capable of generating the normal 
hydroxylated metabolites of estrone that are found in vivo (Bradlow et al., 1995), although 
their ratios were not the same in relation to breast cancer incidence as those found allegedly 
in vivo. 
 
The benzoate esters of both nonyl phenol and estradiol were both active in a rodent 
uterotrophic assay, but inactive in a yeast cell assay, probably due to low levels of ester 
hydrolysis in vitro (Odum et al., 1997). These results could be explained if yeast cells 
possess selective esterase activity, and could account for the discrepancies between in vitro 
and in vivo data observed for the same chemicals. 
 
It is of course feasible that false positive data could be generated in vitro due to a lack of 
detoxification. In this context, it is of interest that some phthalate metabolites, such as mono-
butyl phthalate and mono-benzyl phthalate, which were estrogenic in a recombinant yeast   56 
screen, were inactive in vivo (Harris et al., 1997). By contrast, the inactivity of certain 
chemicals in vitro (e.g. some PCBs in the MCF-7 cell proliferation assay) might be due to an 
inability of the breast cancer cells in culture to convert the chemicals to reactive forms. 
 
There is also some information concerning a human adrenocortical carcinoma cell line 
(H295R), which is being used to detect chemicals that affect steroidogenesis (hormone 
synthesis) (Johanssen et al., 2002). This cell line expresses CYPs 11A, 17, 21 and 11B1.   
 
4.2.2  The potential to use genetically-engineered cell lines 
In addition to the many cell lines that have been genetically engineered to express CYP 
enzymes and various phase 2 enzymatic reactions, there are several genetically-engineered 
mammalian cell lines that have been developed to express human or mammalian nuclear 
receptors for a variety of steroid classes (e.g. estrogens, prostagens and androgens). These 
receptors are expressed in conjunction with their respective response elements linked to 
promoter regions for a reporter gene, together with the reporter gene itself. Unfortunately, 
none of these cell lines were also transfected for metabolising enzymes, and yet some of 
them (e.g. COS and Hep G2) have been used to study metabolism or endocrine disruption in 
separate studies. However, Mak et al., (1999) have developed a novel in vitro screen for 
aromatase inhibitors that involves the use of a yeast strain that co-expresses human 
aromatase CYP19 and the mouse AR receptor as well as an androgen-responsive ß-
responsive reporter plasmid.  
 
One of the problems that were identified at a recent ECVAM workshop is the limited 
number of CYPs that can be incorporated into one cell line. This would mean that at present 
it will remain difficult or even impossible to study the impact of a chemical upon a chain of 
metabolising enzymes where the reaction product of the one is the substrate for the other, as 
was demonstrated for methoxychlor (see above), in genetically engineered cell lines. 
Similarly it would be difficult at present to study the impact of metabolism on the endocrine 
effect of a chemical in genetically engineered cells, if several enzymes could form the same 
or even different but equally active metabolites.   57 
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5.  Proposals to develop a framework for the simultaneous 
testing of endocrine disruption and metabolism 
5.1  Tiered approach including determination of the likelihood of systemic 
exposure 
In order to replace the animal testing of cosmetics by in vitro tests, a tiered approach was 
proposed for these substances. In a first tier the likelihood of systemic exposure would be 
predicted from dermal absorption tests, (Q)SPR approaches, kinetic modeling and cell based 
assays (ECVAM 2003). A tier 2 battery was proposed consisting of (Q)SPR approaches, 
plasma protein binding, kinetic modeling, blood/tissue partitioning tests and metabolism 
(biotransformation) assessments (ECVAM 2003). Substances that will likely be systemically 
available will be used in the third tier, which involves toxicity testing of the substances with 
determination of their potency (ECVAM 2003). One option could be to prioritize potential 
EDs and limit further testing to those compounds that are likely to be absorbed using the first 
tier of the approach for cosmetics. For cosmetics the main route of exposure may be through 
skin absorption because of the way these chemicals are used. EDs may enter via the oral 
route (e.g. food, drinking water), via inhalation (e.g. the spraying of certain pesticides) or 
through the skin (e.g. cosmetics). In order to fully rely on these approaches, all routes of 
exposure thus need to be extensively covered by rigorously validated methods. Substances 
that could be taken up by neonates however should be tested generally because the intestinal 
barrier in neonates may be permeable to compounds that would not pass through the 
intestinal barrier at a later age. In particular for persistent substances like certain pesticides, 
it may be important to consider the site in the organism where the parent compound is 
stored, where the metabolites are formed and where those metabolites might be stored in 
turn. A second tier for ED screening could then take into account the potency of the 
chemicals at hormonal targets, together with in vitro data on metabolism obtained separately, 
in order to further prioritize potential EDs for in vitro testing. As the development and 
validation of methods to specifically detect endocrine disruption is ongoing at OECD we 
refer to this effort for further details. In later stages when tests will be available that can take 
into account metabolism and endocrine targets simultaneously, these should be preferably 
used.   59 
 
Evidently, any information obtained from in vivo testing could also be used in a final 
framework for the combined testing of ED activity of chemicals and of their metabolism. 
Such information may be obtained from assays that are specifically aiming at endocrine 
endpoints like the uterotrophic assay or the Hershberger assay that are being validated, but it 
may also be obtained from other validated toxicity assays. 
 
5.2  In vitro methods to study metabolism 
5.2.1 Screening tests for metabolism 
In order to identify the most important metabolic pathways, human liver fractions or 
genetically-engineered cell lines could be incubated with the chemical, followed by 
quantitative analysis with techniques such as liquid chromatography (LC) and mass 
spectrometry (MS) (Doehmer et al., 1999; Kassahun et al., 2001). The separation and 
identification of metabolites by HPLC or GC would be more time consuming than the 
application of modern approaches like LC/MS/MS. 
 
A priority put forward at a recent ECVAM workshop is the development of a general test to 
determine in vitro metabolism. This approach would allow the detection of compounds that 
are unlikely to be metabolised and for which metabolism may reasonably be excluded as a 
mechanism contributing to toxicity. Nevertheless it can be anticipated that the largest part of 
chemicals will be metabolised. If metabolites can be identified and isolated, or synthesized 
in sufficient quantities, they could be tested in assays that aim to detect ED activity 
(Freyberger and Scholz 2004). At present this approach may not be possible for large scale 
screening. 
 
To screen for metabolic stability, i.e. the property of a compound not to be metabolised, it is 
possible to use microsomes, human hepatocytes or genetically-engineered cell lines 
expressing human biotransformation enzymes. These approaches involve the incubation of 
the chemical with the cells or microsomes, followed by enzyme kinetic studies based on 
chromatographic procedures, such as high performance liquid chromatography (HPLC) and 
LC-MS (Linget & Vignaud, 1999). The exclusive use of microsomal preparations may give   60 
misleading results, because phase II enzymes, which are predominantly cytosolic enzymes  
playing a crucial role in the metabolic biotransformation of chemicals, may be missing. In 
some cases, this problem can be solved by the exogenous addition of cofactors such as UDP-
glucuronic acid (UDPGA) for glucuronidation, and 3’-phosphoadenosine-5’-
phosphosulphate (PAPS) for sulphation (Swales & Utesch, 1998). Whether the addition of 
other factors such as glutathione and acetyl CoA are required should also be considered. 
 
For the assessment of inhibitory interactions with CYP enzymes, the most popular 
approaches involve the use of genetically-engineered cell lines containing only one specific 
human CYP isoform (Coecke et al., 2000) in culture or microsomes thereof (Miller V.P., et 
al. 2000). The effect on the biotransformation of the substrate is dependent on the 
concentrations of both the inhibitor and the substrate, determined by the inhibition constant, 
Ki, of the inhibitor and the Michaëlis-Menten constant, Km, of the substrate. The test 
compounds are incubated with the cultures or the microsomes in the presence of CYP 
substrates. Quantification can then be performed by appropriate fluorescence analysis which 
would probably be the most time saving method especially when performed in microplates, 
HPLC or LC-MS. In situations where more than one enzyme isoform is present, the use of 
complex in vitro models, such as human hepatocyte cultures (Li et al., 1999) is advised, so 
that inhibition and metabolism can be evaluated at the same time.  
 
The use of S9 in combination with an assay for endocrine disruption testing may have a 
number of shortcomings. In cases where an animal source of S9 is used, there might be 
important species differences with regard to prediction of human toxicity. When human 
sources of S9 are available, the amounts are low or limited. Even in cases where a human 
source of S9 would be available in sufficient quantities for screening, the matter of a 
reproducible degree of induction and the potential large experimental variability will 
probably remain an issue to be resolved. Some preliminary findings support the idea that 
human S9 can be used in practice (Yoshihara et al. 2001, 2004). It may be worthwhile to 
search for sources of human S9 and investigate their potential usefulness for incorporation 
into in vitro screening tests. Despite possible difficulties and shortcomings, incorporation of   61 
S9 in ED testing is a likely alternative for inclusion of metabolic capacity for large scale 
testing in the near future. There is some literature that demonstrates the possible usefulness 
of a combination of S9 and ED targets (see section 1.4.3, 2.3 and 4.1), and it is a validated 
means of introducing metabolism in the context of mutagenicity testing. It may also be a way 
of integrating metabolic capacity into tests with other endpoints than those which are 
envisaged for ED testing now, according to future availability. It would be necessary to 
establish the importance of the incubation time with S9, since this will not only determine 
the amount of metabolite formed, but it may also have an impact on cell toxicity. 
 
5.2.2   Induction of biotransformation enzymes 
Xenobiotics taken up by the human body may induce de novo synthesis of enzyme 
molecules (including phase I and phase II biotransformation enzymes) as a result of 
increased transcription of the respective gene. An increase in enzyme activity may also be 
observed as a result of enzyme stabilisation (Coecke et al., 1999). 
 
Various in vitro metabolically-competent models have been proposed for the detection of the 
induction of CYPs, including precision-cut liver slices, short-term and long-term hepatocyte 
cultures, liver-derived cell lines expressing or re-expressing biotransformation enzymes, and 
highly differentiated human cell lines (Coecke et al., 1999, Gomez-Lechon et al., 2001). For 
detecting enzyme induction, these in vitro methods involve the use of endpoints such as: a) 
the activity of the biotransformation enzymes (and, if appropriate, their individual 
isoenzymes); b) protein levels, by using techniques such as immunoblotting or HPLC; and c) 
mRNA levels, by using Northern blotting, e.g. via the nuclease protection assay or the 
reverse transcriptase polymerase chain reaction (Coecke et al., 1999). 
 
Although there are technical difficulties associated with the cryopreservation of hepatocytes, 
a number of cryopreserved hepatocyte cultures have been used for enzyme induction studies 
(Hengstler et al., 2000). To date, no prevalidation study has been carried out on methods for 
identifying the capacity of compounds to induce biotransformation enzymes. However, 
ECVAM initiated a prevalidation study (Coecke et al., 1999) on the use of human 
hepatocyte sandwich cultures (LeCluyse, 2001).   62 
 
Since many hormones - in particular those that are at present considered most prone to 
endocrine disruption - act on NRs that regulate gene expression, EDs can and may also 
interact at this level, inducing and inhibiting enzyme mediated pathways, beyond the ER and 
AR. While awaiting tests that can reliably determine the potential of enzyme induction in 
vitro, it might be worthwhile to validate existing ligand binding and transfection assays for 
AhR (Seidel et al. 2000; Ziccardi et al. 2000; Nagy et al. 2002; Rogers and Denison 2002), 
CAR  and PXR. For instance phthalic acid and nonylphenol, but not bisphenol A increased 
transcription related to PXR activation and increased CYP3A1 mRNA in rat liver 
(Masuyama et al. 2000). Two non-hydroxylated parent PCBs (PCB 118 and 153), trans-
nonchlor and triclosan have also been shown to activate the human PXR in vitro (Jacobs et 
al. 2005). This would not only identify potential enzyme inducers that require further 
investigation, but also potential EDs that interact with these receptors and that otherwise 
would not have been detected. 
 
5.2.3   Models for evaluating polymorphic effects on metabolism 
Amino acid substitution or deletion due to genetic variation can result in reductions, or even 
loss of the activities of phase I or phase II biotransformation enzymes. Certain individuals 
exhibit a severely compromised ability to metabolise chemicals that are specific substrates of 
these polymorphic enzymes, which can lead to serious toxic side-effects (Wolf & Smith, 
1999).  
 
The acetyltransferases, NAT1 and NAT2, represent the best-understood polymorphic 
enzymes. Other phase II enzymes, such as SULTs, UGT, and GST, are known to exhibit a 
variety of polymorphic variants, and understanding of their functional genetic diversity and 
relevance to ED mechanisms is improving (Burchell et al., 1998, 2000; Eaton & Bammler, 
1999; MacGregor et al., 2001;  Glatt, 2000). For example, as discussed earlier, SULTs are an 
important route for steroid modulation that can be modulated at  physiological 
concentrations. (Waring & Harris, 2005). 
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Although genetic polymorphisms of metabolising enzymes are considered as being 
potentially important for endocrine disruption because it might make a group of people more 
or less susceptible for the enzymes’ action, it may not constitute the highest priority to 
establish the possible hazards that chemicals have to induce hormonal effects. Genetic 
polymorphism is probably more important for epidemiological monitoring. 
 
5.3  Approach to combine the in vitro study of endocrine disruption and 
metabolism 
If hormonal targets were to be used exclusively for screening, there is a high likelihood that 
one would miss a number of EDs that require enzymatic activation. It would also be possible 
that some false positives would be detected since compounds that would be very rapidly 
metabolised and thus be inactive in vivo might be active on an in vitro target when studied in 
the absence of metabolism. Although this might be acceptable in a testing scheme to detect 
hazards, it is unacceptable for the performance of risk assessments. Furthermore, false 
positives might incur large and unnecessary economic costs. The most efficient way to 
effectively lower risks of exposure to unknown EDs might therefore be to develop a 
framework that combines in vitro tests on both metabolism and hormonal targets. 
 
A major point with regard to validation of assays will be to make sure that the metabolic 
competence that will be applied to an in vitro system simulates the mix of diverse enzymes 
that is of importance in vivo, and that the delicate balance between activation and 
deactivation of compounds that may exist in vivo, is preserved. 
 
In the short term, the quickest and easiest way to implement such test may be to incorporate 
S9 into acceptable indicator tests for endocrine disruption in a fashion similar to the testing 
for mutagenicity. Possible problems like protein binding, the potential influence of the 
incubation time with S9, and cytotoxicity of S9, and substances used to induce enzymes in 
the S9, should be investigated and solved. It will be imperative to be able to reproducibly 
activate the enzymatic system. The importance of the species originating the S9 should be 
addressed. If the risk assessment for humans is the ultimate goal, then a human based system   64 
is preferred. If prediction of risk for wildlife is the aim, then another species may be a better 
source for in vitro studies. Due to the potential problem of standardization of S9 from human 
origin and because further testing may involve tests on laboratory animals, another 
mammalian S9 such as that isolated from rats may also be considered. The intention of 
proposing the use of S9 is to reduce at this stage the potential of false negative results, but 
validation should take into account that not too many false positives would be detected 
because that would lead to unnecessary further testing. On the other hand, care should be 
taken that the metabolic capacity in vitro would not be too high in comparison to the 
metabolic activity in vivo, since otherwise active compounds may not be considered as an 
ED only because of an unrealistically high degradation of the xenobiotic in the in vitro test. 
While the use of S9 is a useful possibility that is available at present, efforts should be made 
to explore more refined methods that may mimic the in vivo situation more precisely. 
 
Although the ideal solution for the simultaneous testing of ED potential and metabolism may 
not be reached in the near future, this should not prevent the use of the best possible 
combination of tests that are already available. If agreement on a framework for testing can 
be obtained, this might also be helpful to identify those tests that may be of utmost need and 
thus should be developed with the highest priority. It is suggested that primary in vitro tests 
(further abbreviated as P) for endocrine disruption at different targets, as described in 
chapter 1.4, should be developed and validated. These may not remain limited to the ERα  
and the AR ligand binding assays or to functional assays but could also include the other 
NRs of the same family like the ERβ , progesterone, glucocorticoid and mineralocorticoid 
receptors and the thyroid receptors. While devising such tests, preference should be given to 
those tests that may be combined most easily with a simultaneous assessment of metabolism 
of the substance under study. Whether or not these receptors should also be incorporated in 
the battery of necessary tests would deserve further investigation. Chemicals that can interact 
with FSH and LH function, can interact at different levels with sex steroids and reproductive 
function. Therefore these two hormones should also be integrated into the framework. It 
seems imperative that functional tests will be developed to discern between agonists and 
antagonists. The combination of tests for antagonism with metabolic capacity will need   65 
particular attention, since the concentration of the agonist used may be affected by the 
presence of metabolising enzymes. In vitro tests to detect metabolism of chemicals (further 
abbreviated MC) could be developed along the lines discussed in chapter 5.2, but evidently 
any information on metabolism that is available from other assays could be used at present to 
decide about the potential ED effects of certain chemicals. Thirdly in vitro tests to detect the 
interference of chemicals with steroid hormone synthesis and metabolism (further 
abbreviated as MH) should be developed but this will be the subject of two separate Detailed 
Review Papers. While the proposed tests would be directed to the testing of the effect of 
chemicals on ED targets, metabolism of the chemical or effect of the chemical on steroid 
metabolism separately, the same tests could in the end be used to combine the testing of the 
influence of chemicals on ED targets in conjunction with the testing of its effect on steroid 
metabolism (further abbreviated as PMH) or in combination with the testing of its own 
metabolism (further abbreviated as PMC). In particular the combination of S9 and a primary 
test may offer a valuable alternative in the short term. Furthermore validated in vivo tests for 
general toxicity (further abbreviated as G and including OECD test 407 for 28 day oral 
toxicity enhanced for ED effects, OECD 415 one generation reprotoxicity and OECD 416 
two generation reprotoxicity) or in vivo tests with rather specific ED endpoints (including 
the uterotrophic and Hershberger assays) could offer information about ED effects. 
 
A framework (Table 6) is proposed that would allow some prediction of the ED potency of 
chemicals while awaiting the availability of validated tests. For the time being, the 
development and validation of tests detecting a hormonal effect or metabolism may be 
simpler than the combination of both. At this moment they may offer a reasonable 
alternative for testing while awaiting combination tests. When a chemical would be inactive 
in all relevant P, MC and MH tests, one can anticipate that it will be probably devoid of ED 
activity but great care should be taken to avoid the occurrence of false negatives. If a more 
affirmative denial of ED effects is required at this stage, using in vivo tests may still be 
required. 
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When a chemical would have an effect in a test that was developed for the measurement of 
steroid metabolism, it can be considered a potential ED. The potency of the substance 
required to reach this decision would still need to be established. Further testing in vivo may 
be required to reach a more definite conclusion or to perform a risk assessment. To exclude 
potential species differences, an animal species known to be sensitive to the endocrine 
mechanism involved to the same extent as humans and for which the in vitro activity was 
confirmed, should be used. If this condition is fulfilled, a chemical that would be inactive in 
vivo, could be considered devoid of ED activity despite its effect on hormone metabolism in 
vitro. 
 
When a chemical would be active in one of the tests developed to study its metabolism, it 
should be evaluated in the primary tests for ED after adding metabolising capacity, 
preferably utilizing the same metabolising entity where it was found active if this is 
compatible with the endocrine target to be tested. If the chemical would be inactive or very 
weak it is likely not an ED. If the chemical would be active as an ED in the presence of 
metabolising capacity, it would need to be considered an ED and in vivo testing may be 
required to reach a more definite conclusion for risk assessment. To exclude potential 
species differences, an animal species known to be sensitive to the endocrine mechanism 
involved to the same extent as humans and for which the in vitro activity was confirmed, 
should be used. If this condition is fulfilled, a chemical that would be inactive in an in vivo 
test that is sensitive to effects caused through the target that was affected in vitro, could be 
considered devoid of ED activity despite its activity in a primary test for ED with additional 
metabolic competence. Obviously, a scientific validation procedure should minimise the 
potential to detect such false positives in vitro. The potency limits determined by in vitro 
tests that would support the decisions to be made still need to be established. 
 
When a chemical would be active in an in vitro test for an endocrine target it should be 
tested further in the presence of metabolic capacity. If it would not be active in same test 
when combined with metabolising capacity, it may considered as probably not an ED 
because of metabolism. To be able to draw that conclusion, it would be imperative to   67 
ascertain that the in vitro system has a metabolising capacity that is representative for the in 
vivo situation. If a chemical would remain active in the presence of metabolising capacity, it 
should be considered a potential ED. Subsequent testing in an appropriate in vivo test may 
facilitate a more validated conclusion of relevance to a risk evaluation. To exclude potential 
species differences, an animal species known to be sensitive to the endocrine mechanism 
involved to the same extent as humans and for which the in vitro activity was confirmed, 
should be used. If this condition is fulfilled, a chemical that would be inactive in vivo could 
be considered devoid of ED activity, despite its in vitro activity. Obviously a validation 
should aim at reducing the number of such false positives in vitro. 
 
In the ideal situation, in vitro testing should precede any in vivo testing. However where 
available, information from in vivo tests is of value. If a chemical would be active in one of 
the general toxicity tests and the available information would suggest an endocrine 
mechanism of action, this can be further investigated in vitro. A positive test result in vitro 
would indicate that the chemical is an ED. 
 
It does not appear likely at present that a chemical will be tested in an in vitro assay that 
would combine a primary endocrine endpoint and metabolism of hormones. However, in the 
event that this might be possible, any active compound should be treated in a similar way as 
one that was found active in separate in vitro assays for a primary endocrine endpoint and 
metabolism of the chemical. In this respect it should be noted that the PMH tests are 
considered less urgent to develop while the MH and PMC tests could be considered 
priorities as they can facilitate most of the conclusions necessary within the context of the 
proposed framework. 
 
The ultimate goal should be to develop tests that would allow implementation of a flow 
chart for ED testing that would start in a first tier with in vitro assessment of systemic 
availability. If there is sufficient evidence to believe that a substance will not be systemically 
available and if it cannot be swallowed by mouth by neonates, the substance can be 
considered as being devoid of ED activity. If there is doubt or relatively large certainty that it   68 
can be systemically available or if it can be swallowed because of its use by neonates, it 
should be further tested. A second tier should consist of tests for interference by chemicals 
with metabolism or synthesis of hormones and tests for endocrine activity in the presence of 
metabolising capacity. At present most attention is given to estrogenic, androgenic and 
thyroid activity but other hormonal and ED pathways may be envisaged as well. If the 
substance would not be active below an agreed and defined concentration in both kinds of 
tests, the substance can be considered to be devoid of potential ED activity. If there is 
activity in the second tier in vitro tests, the substance should be tested further in vivo. 
Possible third tier tests could include an enhanced OECD 407, OECD 415, OECD 416, 
uterotrophic assay or Hershberger assay or any other test that might become available and be 
considered relevant in the future. 
 
6. CONCLUSIONS  AND  RECOMMENDATIONS 
Clearly, it is crucially important that in vitro methods for testing EDs should take account of 
the need to provide a metabolising system, either in the form of subcellular enzyme 
fractions, or by using cells that have been rendered metabolically competent. This is based 
on the fact that there is sufficient information showing that endogenous steroids and EDs are 
extensively metabolised by phase I and II enzymes in both the liver and hormonally-active 
tissues, and that such metabolism can lead to the activation or inactivation of steroids and, 
with regard to ED’s to detoxification but also to the formation of active metabolites.  Despite 
the fact that there are several technical problems with using sub-cellular metabolising 
systems in assays for testing EDs, there is sufficient evidence in the literature to show that 
these limitations can be overcome and that the presence of such enzymes modulates the 
chemical toxicity of several different types of EDs. 
 
The absence of metabolism in in vitro assays for EDs could give rise to false positive data 
(due to lack of detoxification) or negative data (lack of activation) arising from the use of the 
tests. This situation regarding the lack of metabolism being incorporated into in vitro assays 
for EDs is equivalent to embarking on developing and validating the Salmonella 
mutagenicity assay (Ames Test) without investigating the need to add liver S9 or   69 
microsomal fractions. Clearly, if this course of action had been followed, the test would 
never have been accepted for mutagenicity, and as a screen for carcinogenicity. It is, 
therefore a serious drawback that currently the use of in vitro assays for EDs is not receiving 
the attention that it deserves, and this will only be rectified when the issue of incorporating 
aspects of metabolism into the assays has been achieved. The contribution of incorporation 
of metabolism into ED testing would be to avoid both false positives and false negatives, to 
be able to make risk assessments with in vitro data on the potency of the chemicals that 
matter more than the parent compound and to better estimate the possible duration of action. 
On the other hand, the development of a system for ED testing incorporating metabolism 
would require careful consideration so as not to generate an unreasonable and unjustified 
number of false positives and false negatives. 
 
Thus, the perceived difficulties of incorporating metabolism into in vitro tests for EDs 
should not deter more research into how this can be achieved.  The development and 
validation of these in vitro assays in conjunction with appropriate metabolising systems 
should be a matter of urgency. 
  
It is recommended that approaches should be developed that can predict systemic exposure. 
Particular attention should be given to the potential oral exposure of neonates. If no systemic 
exposure is expected, chemicals could be regarded as being devoid of ED effects. Obviously 
not only tests but also criteria that would allow interpretation of the results should be 
provided. The possibility to use (Q)SARs for the analysis of potential ED effects through 
well specified mechanisms and/or for the analysis of potential interference with the 
metabolism of endogenous hormones and exogenous compounds, as well as the for the 
prediction of metabolism of chemicals by phase I and II enzymes, should continue to be 
explored and developed. At present there are not yet validated in vitro tests incorporating 
metabolic competence to measure the effect of chemicals on endocrine targets in vitro. Even 
separate testing for endocrine disruption or the potential of chemicals to be metabolised or to 
interfere with metabolism is not yet sufficiently validated. For the time being available data 
from in vitro tests for endocrine action and from metabolism tests could be used to further   70 
prioritization of potential EDs for further testing. It would be advisable that criteria should 
be put forward to take this decision. In the future, tests should be made available that 
combine both testing for metabolism and endocrine effects and studies should be initiated 
that will gain more knowledge about the incorporation of metabolic capacity in existing 
functional tests or the incorporation of endocrine molecular targets into existing cell lines 
with metabolic capacity. 
In the short term inclusion of S9 into in vitro ED tests may be the only reasonable alternative 
that could be made available. In the long term, it is recommended that reports in preparation 
concerned with the generation of genetically-engineered mammalian cell lines containing 
steroid hormone NRs, their response elements and reporter genes, together with genes 
expressing specific metabolising enzymes are assessed for feasibility for high throughput 
screening and subsequent  submission for (pre) validation purposes.  Such multiple 
expressing cell lines could then be utilised to investigate the metabolic activation and 
detoxification of potential EDs in vitro. Whether a substance is an ED or not  can currently 
only be definitely established by in vivo experiments, however  in silico and in vitro 
screening with the incorporation of metabolism would result in a more adequate 
prioritisation for further testing. It would indeed become possible to test the most reasonable 
dose or dose-range of the compounds that would be most likely to produce relevant effects. 
If a substance is suspected of being a potential ED on the basis of in vitro tests using 
enzymes and molecular targets of human origin, and the substance is going to be finally 
tested in vivo, it is advised to first confirm activity in tests in vitro with materials obtained 
from the animal species and strain that will be used for the in vivo test. 
 
The assessment of intrinsic metabolising capacity of the cells used in ED testing is very 
important. On the one hand it could be used to a certain extent as a source of metabolic 
capacity; on the other hand it would constitute an inherent part of the test system that needs 
to be well described in order to correctly interpret results obtained. It may be worthwhile to 
identify substances that increase in endocrine disruption capabilities compared to those that 
become inactivated by metabolism. If one could construct a list of parent compounds and 
their metabolites with known effect on an endocrine disrupting target, one could pre-screen   71 
in silico and test all of these substances in any new in vitro test that is being validated for 
endocrine disruption. Thus it might be possible in a short time frame to have a first 
indication of the metabolic capacity of the cells used in the test and thus the possible 
relevance of that residual metabolic capacity to develop a combined test. 
 
It is also recommended that there should be an investigation into the relevance of using the 
prostaglandin H synthase (PHS) system for metabolising EDs.  As described earlier, PHS 
activity is expressed in a wide range of tissues, and this includes hormonally-active organs, 
such as the uterus (e.g. by uterine stromal cells in vitro (Liu et al., 2001)).  
   
Lastly, it is most important that due consideration be given to the ability of indicator cell 
lines to conduct both phase I and II metabolism, to avoid the possibility of generating a large 
amount of false positive data due to the formation of hydroxylated metabolites that will 
possess structural features on the molecules that predispose them to binding to hormone 
receptors, without the possibility for these to be detoxified by conjugation.  
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Table 1 
EXAMPLES OF CELL LINES AND OTHER CELL TYPES USED IN CELL 
PROLIFERATION AND TRANSCRIPTIONAL ACTIVATION ASSAYS FOR TESTING 
ENDOCRINE DISRUPTORS (Combes, 2000a and references therein) 
 
Cell line  Estrogenicity  Androgenicity  Notes 
CHO No  Yes   
CHO-K1 Yes No  Metabolises  vinclozolin 
COS-1  Yes  No  Easy to transfect with recombinant CYPS 
BG-1 Yes  No   
CV-1 No  Yes    Easy to transfect. Possesses 17α - oxidase and 
5α - reductase  
ELT-3  Yes  No  Also possesses PR receptor 
HEC-1  Yes  No  Also possesses PR receptor 
HEK 293  Yes  No   
Hep G2  Yes  Yes  Possesses some residual P450 activity and can 
be transfected with various CYPs, but has no 
ERα  or β  
Hep 1c1c7  Yes  Yes  Possesses Ah receptor 
HeLa Yes  No   
Ishikawa  Yes  No  Also possesses PR receptor 
MCF-7 Yes  No  Also  possesses  PR receptor and metabolises a 
range of estrogens. 
MDA-MB Yes  Yes  Very low level of ERβ ; GR receptor also 
present 
PC-3 No  Yes   
PC-12 No  Yes   
PALM No  Yes   
T47D  Yes  No  Also possesses PR receptor 
ZR-75  Yes  No  Also possesses PR receptor 
Yeast  Yes  Yes  Residual P450 activity present.  
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 Table 5  
EXAMPLES OF TYPICAL ACTIVITY ASSAYS AND AVAILABILITY OF COMMERCIALLY 
AVAILABLE ANTIBODIES IN ORDER TO ANALYSE XENOBIOTIC-METABOLISING CYP 
ENZYMES. 
 
Activity Assay 
Commercial availability of antibody 
CYP1A1 7-Ethoxyresorufin  O-deethylase  Yes 
CYP1A2 7-Methoxyresorufin  O-demethylase; 
Phenacetin O 
Yes 
CYP1B1 7-Ethoxyresorufin  O-deethylase; 
Phenacetin O-Deethylase 
Yes 
CYP2A6 Coumarin  7-Hydroxylase  Yes 
CYP2B6 (S)-Mephenytoin  N-Demethylase; 
Cyclophosphamid 4-hydroxylase 
Pentoxyresorufin O-depentylase 
Benzyloxyresorufin O-debenzylase 
Yes 
CYP2C9 Tolbutamidhydroxylase 
Diclofenac 4‘-Hydroxylase 
Yes 
CYP2C19 Mephenytoin  4‘-hydroxylase  Yes 
CYP2D6 Debrisoquinhydroxylase 
Dextromethorphan 
Bufuralol 1‘-hydroxylase 
Yes 
CYP2E1 Chlorzoxazon  6-hydroxylase  Yes 
CYP3A4 Testosteron  6ß-hydroxylase 
Midazolam hydroxylase 
Yes 
CYP3A5 Testosteron  6ß-hydroxylase  Yes  
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Figure 1. P450 Transcription factors (Jacobs, 2004) 
P450 Transcription Factors
CYP4A
Fatty acid metabolism
RXR PPARα
CYP2B
Xenobiotic, Steroid metabolism
RXR CAR Steroids, Xenobiotics
Fatty acids, Fibrates
CYP3A
Xenobiotic, Steroid metabolism
RXR PXR Steroids, Xenobiotics
CYP1A
Xenobiotic metabolism
AhR ARNT Steroids, Xenobiotics  124 
Figure 2. Key receptors and P450 in the steroidogenic pathway (Jacobs, 2004) 
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Figure 3. The synthesis of different steroid hormones with indications of the roles 
played by some P450s (Mensah-Nyagan et al., 1999) 
 